Document:

exv10w46

Exhibit
10.46

OMEROS CORPORATION

AGREEMENT FOR ANTIBODY DEVELOPMENT

This Agreement for Antibody Development (this “Agreement”) is between Omeros Corporation
(“Omeros”), a Washington corporation having an address at 1420 Fifth Avenue, Suite 2600, Seattle,
Washington 98101, and North Coast Biologics LLC (“North Coast”), a Washington Limited Liability
Company having an address at 2815 Eastlake Avenue East, #300, Seattle, Washington 98102, and is
effective as of October 31, 2008 (the “Effective Date”). Omeros and North Coast may be referred to
herein each as a “Party” or together as the “Parties”.

Omeros’ business includes the research and development of pharmaceuticals and biological
therapeutic products. North Coast is in the business of the discovery of humanized recombinant
antibodies from rabbits. Omeros wishes to access North Coast’s expertise to isolate and optimize
antibodies to human MASP-2 and additional targets, which Omeros will further develop and
commercialize, as further described below, and North Coast wishes to provide such expertise to
Omeros.

Therefore, for the above and other consideration, Omeros and North Coast hereby agree as follows:

1 Key Definitions

	1.1	 	“Additional Target Therapeutic” shall mean a biological therapeutic that contains a North
Coast-Originated Additional Target Antibody, the manufacture, sale, offer for sale or use of
which, were it not for Omeros’ ownership of the Omeros Antibody Patents, would infringe any
valid and enforceable claim(s) of any issued patent or any patentable claim(s) of any pending
patent application included within the Omeros Antibody Patents in the country or countries in
which such products are offered for sale, sold, manufactured or used.
	 
	1.2	 	“Additional Targets” shall mean the therapeutic targets listed on Exhibit A attached
hereto and any other therapeutic targets identified by Omeros to North Coast during the Option
Period (as defined below); provided, however, that Additional Targets shall not include the
following targets for which North Coast has previously granted a third party an option to have
North Coast develop antibodies against such targets pursuant to a written agreement executed
prior to the date of this Agreement, if and only if such following targets are timely elected
by such third party under the prior agreement prior to December 1, 2008 and only with respect
to the ScFV format of antibody fragments against such elected following targets for which
North Coast is precluded from developing for Omeros pursuant to the terms of the prior
agreement: [†].
	 
	1.3	 	“Chimeric Antibodies” shall have the meaning set forth in the applicable Research Plan (as
defined in Section 2.3).

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

1

 

	1.4	 	“Combination Product” shall mean any (a) MASP-2 Therapeutic containing both a North
Coast-Originated MASP-2 Antibody and one or more additional pharmaceutically active agent(s)
that do not constitute a North Coast-Originated MASP-2 Antibody and
(b) Additional Target Therapeutic containing both a North Coast-Originated Additional Target
Antibody and one or more additional pharmaceutically active agent(s) that do not constitute a
North Coast-Originated Additional Target Antibody.
	 
	1.5	 	“Deliverables” shall mean the deliverables to be provided by North Coast to Omeros under any
Research Plan.
	 
	1.6	 	“First Due Date” and “Second Due Date” shall mean the dates set forth in a Research Plan by
which North Coast agrees to deliver (i), for the First Due Date, [†] and (ii) for the Second
Due Date, [†], (all of such Deliverables together, the “First Due Date Deliverables” and the
“Second Due Date Deliverables”, respectively). The First and Second Due Dates in a Research
Plan shall be mutually agreed to by Omeros and North Coast at the time of execution of the
Research Plan and shall be automatically extended by the number of days that Omeros takes to
perform the matters assigned to in the Research Plan in excess of the number of days allotted
to Omeros for such matters in the Research Plan, unless such failure is caused by North Coast
not timely providing any of the Services and Deliverables by the deadlines set forth in the
Research Plan.
	 
	1.7	 	“FDA” shall mean the US Food and Drug Administration.
	 
	1.8	 	“IND” shall mean an Investigational New Drug Application, if submitted to FDA, or
corresponding application to permit the commencement of clinical trials for the evaluation of
a pharmaceutical or biological therapeutic if submitted to another Regulatory Agency.
	 
	1.9	 	“Intellectual Property Rights” shall mean all inventions, ideas, discoveries, issued,
reissued or reexamined patents, pending and future patent applications, continuation and
continuation-in-part patent applications, divisional patent applications, utility models,
inventor’s certificates, trade secrets, know-how, copyrights, computer programs, databases and
trademarks.
	 
	1.10	 	“Lead Candidate” shall have the meaning set forth in the applicable Research Plan.
	 
	1.11	 	“MASP-2” shall refer to human mannan binding lectin-associated serine protease 2.
	 
	1.12	 	“MASP-2 Therapeutic” shall mean a biological therapeutic that contains a North
Coast-Originated MASP-2 Antibody, the manufacture, sale, offer for sale or use of which, were
it not for Omeros’ ownership of the Omeros Antibody Patents, would infringe any valid and
enforceable claim(s) of any issued patent or any patentable claim(s) of any pending patent
application included within the Omeros Antibody Patents in the country or countries in which
such products are offered for sale, sold, manufactured or used.
	 
	1.13	 	“Net Sales” shall refer, with respect to an Omeros Therapeutic, to (a) the gross total of the
monetary amounts invoiced and collected by Omeros or, if Omeros has licensed 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

2

 

	 	 	manufacturing and
distribution rights to a licensee, by Omeros’ licensee, for the initial sale or distribution
of such Omeros Therapeutic, but excluding any amounts invoiced or collected by parties other
than Omeros or Omeros’ licensee for subsequent sales or distribution provided no part of such
amounts invoiced or collected by such parties is directly or indirectly paid to Omeros or
Omeros’ licensee, less (b) the sum of the following actual and customary deductions where applicable: cash, trade, or quantity discounts; sales,
use, tariff, import/export duties or other excise taxes, and any other governmental taxes
imposed on particular sales; transportation charges and allowances; sales commissions to
third parties (but excluding sales commissions to Omeros’ employees); wholesale charge backs;
distributor fees; Medicare/Medicaid rebates; customer rebates; refunds for recalls; and
allowances or credits to customers because of rejections or returns, provided such deductions
are documented. If a North Coast-Originated Antibody is sold in combination with one or more
additional active agents as a Combination Product, Net Sales shall be the product obtained by
multiplying Net Sales of the Combination Product by the fraction A/(A+B) where A is the sales
price of the North Coast-Originated Antibody in the Combination Product when sold separately
in an Omeros Therapeutic including a North Coast-Originated Antibody as the only active agent
and B is the total sales price of all additional active agents in the Combination Product
when sold separately in a pharmaceutical or biologic therapeutic product including such
additional active agents as the only active agents. If the North Coast-Originated Antibody
and the other active agents are not sold in separate pharmaceutical or biologic therapeutic
products, the portion of the total cost of the Combination Product attributed to the North
Coast-Originated Antibody shall be a fraction, the numerator of which shall be the cost of
the North Coast-Originated Antibody and the denominator of which shall be the total cost of
the Combination Product, and the fraction shall be multiplied by the sales price of the
Combination Product to arrive at Net Sales. For purposes of this paragraph, the acquisition
of Omeros Therapeutics from Omeros as part of an acquisition or other transfer or conveyance
of all or a part of the assets of Omeros’ business to which this Agreement pertains, or as
part of a merger, acquisition, reorganization or other change of control of Omeros, shall not
be considered a sale or distribution of Omeros Therapeutics.
	 
	1.14	 	“North Coast-Originated Additional Target Antibody” shall mean any Additional Target antibody
or antibody fragment that specifically binds to an Additional Target or portions thereof that
was isolated and/or developed for and delivered to Omeros by North Coast under this Agreement
or that is derived from an Additional Target antibody or antibody fragment that was isolated
and/or developed for and delivered to Omeros by North Coast under this Agreement.
	 
	1.15	 	“North Coast-Originated Antibody” shall mean any North Coast-Originated MASP-2 Antibody or
North Coast-Originated Additional Target Antibody.
	 
	1.16	 	“North Coast-Originated MASP-2 Antibody” shall mean any MASP-2 antibody or antibody fragment
that specifically binds to 

MASP-2 polypeptides or portions thereof that was isolated and/or
developed for and delivered to Omeros by North Coast under this Agreement or that is derived
from an MASP-2 antibody or antibody fragment that was

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

3

 

	 	 	isolated and/or developed for and
delivered to Omeros by North Coast under this Agreement.
	 
	1.17	 	“Omeros Antibody Patents” shall mean (a) all patent applications and patents that claim North
Coast-Originated MASP-2 Antibodies, MASP-2 Therapeutic compositions, or methods of producing
North Coast-Originated MASP-2 Antibodies or MASP-2 Therapeutic compositions and (b) all patent
applications and patents that claim North Coast-Originated Additional Target Antibodies, Additional Target Therapeutic compositions, or
methods of producing North Coast-Originated Additional Target Antibodies or Additional Target
Therapeutic compositions; provided, however, that the Omeros Antibody Patents shall exclude
any patents or patent applications owned by third parties.
	 
	1.18	 	“Optional Candidate” shall have the meaning set forth in the applicable Research Plan.
	 
	1.19	 	“Overall Objective” shall mean the isolation and optimization of a North Coast-Originated
Antibody (as described in each Research Plan) that is suitable for advancement by Omeros
through preclinical and clinical development and ultimate manufacture, commercialization,
distribution and sale in the form of one or more Omeros Therapeutics.
	 
	1.20	 	“Omeros Therapeutic” shall mean any MASP-2 Therapeutic or Additional Target Therapeutic.
	 
	1.21	 	“Regulatory Agency” shall mean FDA or corresponding foreign national or international agency
that regulates and approves the clinical testing, marketing and sale of pharmaceuticals and
biological therapeutics.
	 
	1.22	 	“Second Generation Candidate” shall have the meaning set forth in the applicable Research
Plan.
	 
	1.23	 	“Services” shall mean the services to be provided by North Coast to Omeros under any Research
Plan.
	 
	2	 	Services and Deliverables
	 
	2.1	 	MASP-2 Antibodies. North Coast shall provide Omeros the Services and Deliverables set forth
in the initial research plan (“Initial Research Plan”) attached to this Agreement as
Exhibit B. As consideration for such Services and Deliverables, Omeros agrees to pay
to North Coast: the Initial Access Fee, MASP-2 cDNA Fee, Optional MASP-2 Candidate cDNA Fee
(if applicable) and the Development Milestone Payments and Sales Royalties (as such terms are
defined in Section 3) with respect to any MASP-2 Therapeutic developed under the Initial
Research Plan, but only to the extent that such amounts become due and payable under the terms
and conditions of this Agreement and the Initial Research Plan.
	 
	2.2	 	Antibodies to Additional Targets.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

4

 

	 	a)	 	Option for Additional Targets. Omeros will have an option (the “Option”),
exercisable during the period beginning on the date of this Agreement and ending on the
earlier of (i) the twelve-(12) year anniversary of the date of this Agreement and (ii)
such time as Omeros’ has exercised the Option with respect to [†] Additional Targets
(the “Option Period”), to have North Coast generate antibodies raised against up to [†]
of the Additional Targets that may be selected by Omeros at Omeros’ sole discretion,
individually or in group(s), during the Option Period. If Omeros elects to exercise
the Option, it shall do so by providing written notice to
North Coast and the Parties will execute a research plan for such Additional Target in
substantially the form attached hereto as Exhibit C, modified as the parties
deem reasonably necessary solely to account for any changes to the process necessary to
develop and validate antibodies to such Additional Target (an “Additional Target
Research Plan”), and North Coast will provide Omeros the Services and Deliverables set
forth in such Additional Target Research Plan.
	 
	 	 	 	If Omeros exercises its Option for an Additional Target, then as consideration for the
Services and Deliverables set forth in the applicable Additional Target Research Plan,
Omeros agrees to pay to North Coast for such Additional Target: the applicable
Subsequent Access Fee (if payable under Section 3.1.a.2), the Additional Target Antibody
cDNA Fee, the Optional Additional Target Antibody cDNA Fee (if applicable) and the
Development Milestone Payments and Sales Royalties (as such terms are defined in Section
3) with respect to any Additional Target Therapeutic developed under such Additional
Target Research Plan, but only to the extent that such amounts become due and payable
under the terms and conditions of this Agreement and the applicable Additional Target
Research Plan.
	 
	 	b)	 	MASP-2 Replacement. Notwithstanding anything to the contrary contained in this
Agreement or the Initial Research Plan, if Omeros determines that in performing the
Services and providing the Deliverables described in Task 1 of the Initial Research
Plan North Coast did not [†], then (i) unless agreed to in writing by Omeros, North
Coast shall continue to perform the Services until delivery of the Deliverables under
the Initial Research Plan in order to achieve the Overall Objective described in the
Initial Research Plan (including, without limitation, reperforming any Services and
Deliverables in Task 1 of the Initial Research Plan) and (ii) at Omeros’ discretion,
upon written notice from Omeros to North Coast (the “MASP-2 Replacement Notice”), the
Parties will enter into an Additional Target Research Plan for an Additional Target
selected by Omeros on the terms and conditions set forth in Section 2.2.a, except that
(1) Omeros will not be required to pay a Subsequent Access Fee with respect to such
Additional Target and (2) such Additional Target will not be counted for purpose of
determining how many remaining Additional Targets are subject to the Option under
Section 2.2.a; provided, however, that North Coast will not be required to enter into
an Additional Target Research Plan for an Additional Target pursuant to this Section
2.2.b(ii) unless Omeros gives North Coast the
MASP-2 Replacement Notice before the date that North Coast provides Omeros a

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

5

 

	 	 	 	Lead Candidate under the Initial Research Plan that meets the applicable Acceptance Criteria
and all of the related Services and Deliverables.
	 
	 	 	 	If Omeros provides North Coast a timely MASP-2 Replacement Notice under Section
2.2.b(ii) and the Parties enter into an Additional Target Research Plan under Section
2.2.b(ii) for an Additional Target then, notwithstanding anything to the contrary
contained in Section 2.4, Omeros may not require North Coast to enter into an Additional
Research Plan under Section 2.4(b) if North Coast fails to deliver to Omeros either the
First Due Date Deliverables within ninety (90) days of the First Due Date under the
Initial Research Plan or the Second Due Date Deliverables within ninety (90) days of the
Second Due Date under the Initial Research Plan; provided,
however, that the preceding limitation to Omeros’ rights under Section 2.4(b) shall only
apply with respect to the Initial Research Plan and not any other Research Plans.
	 
	 	c)	 	[†].
	 
	 	d)	 	FMAT Machine. North Coast acknowledges receipt of [†] from Omeros on October
21, 2008 (the “FMAT Payment”), which amount North Coast used to [†] the purchase price
of a Fluorometric Microvolume Assay Technology machine (the “FMAT”). As consideration
for the FMAT Payment, notwithstanding anything to the contrary contained in this
Agreement:
	 
	 	 	 	2.2.d.1 The Additional Target for which Omeros exercises its Option (but not including
the Additional Target that Omeros selects pursuant to Section 2.2.b, if any, which will
be subject to the terms and conditions of Section 2.2.b) and designates in writing at
the time of such exercise as being linked to the FMAT Payment (the “FMAT Target”) shall
be subject to the terms and conditions of Section 2.2.a, except that (i) Omeros will not
be required to pay any Development Milestone Payments or Sales Royalties with respect to
any Omeros Therapeutic that is developed under the Additional Target Research Plan for
the FMAT Target, (ii) the FMAT Target will not be counted for purpose of determining how
many remaining Additional Targets are subject to the Option under Section 2.2.a and
(iii) unless North Coast has delivered to Omeros the FMAT Repayment Amount (as defined
below) prior to Omeros’ exercise of its Option for the FMAT Target, if the FMAT Target
is the first Additional Target selected by Omeros during a calendar year in which a
Subsequent Access Fee would be payable by Omeros under Section 3.1.a.2, then,
notwithstanding anything to the contrary contained in this Agreement, Omeros will not be
required to pay a Subsequent Access Fee for the FMAT Target and for purposes of
determining the Subsequent Access Fee under Section 3.1.a.2 for any Additional Target
selected during the same calendar year or in any subsequent calendar year(s), Omeros
shall be given credit for the payment of a Subsequent Access Fee during the calendar
year in which it exercised its option for the FMAT Target. The “FMAT Repayment Amount”
is an amount equal to the FMAT Payment plus interest on such amount calculated from the
date of this Agreement on the basis of a three hundred sixty (360) day period at a per
annum rate equal to the interest rate of [†].

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

6

 

	 	 	 	If the FMAT Target is the first Additional Target selected by Omeros during a calendar
year in which a Subsequent Access Fee would be payable by Omeros under Section 3.1.a.2,
and if upon Omeros’ exercise of its Option and designation of the FMAT Target, North
Coast reasonably determines that it would be financially unable to provide the required
services for generation of antibodies against the FMAT Target in accordance with the
applicable Additional Target Research Plan, North Coast may request that Omeros pay the
otherwise applicable Subsequent Access Fee for the FMAT Target in accordance with
Section 3.1.a.2 and, unless Omeros elects not to proceed at that time with the FMAT
Target (in which case it may reserve election of an FMAT Target for a later time),
Omeros shall pay the otherwise applicable Subsequent Access Fee (the “FMAT Access Fee”).
If Omeros has paid the FMAT Access Fee, then upon Omeros’ written election either (a)
an amount equal to [†] the FMAT Access Fee shall be credited against the first to become
due and payable of (i)
the Additional Target Antibody cDNA Fee for the FMAT Target or (ii) an Additional Target
Antibody cDNA Fee for another Additional Target, or

(b) the first Development Milestone that becomes due thereafter for the [†].
	 
	 	 	 	If North Coast fails to deliver either the First Due Date Deliverables by the First Due
Date specified in an Additional Target Research Plan or the Second Due Date Deliverables
by the Second Due Date specified in an Additional Target Research Plan for the FMAT
Target, then upon written notice to North Coast, Omeros shall have the right to
designate any other Additional Target as the FMAT Target in place of the originally
designated Additional Target, and all of the provisions in the above paragraph shall
apply to the redesignated FMAT Target in place of the originally designated Additional
Target, with North Coast being relieved of any further work on the originally designated
Additional Target and Omeros being relieved of any further financial obligations
concerning the originally designated Additional Target.
	 
	 	 	 	2.2.d.2 [†].
	 
	 	 	 	[†].
	 
	 	 	 	[†].
	 
	 	 	 	2.2.d.3 Omeros shall be provided free use of and access to the FMAT machine at North
Coast’s facility in Omeros’ research and development programs, at times to be mutually
agreed for convenience to both parties and without undue interruption of North Coast’s
activities.
	 
	 	 	 	2.2.d.4 If under the terms and conditions of the Additional Target Research Plans for
the first three (3) Additional Target for which Omeros exercises its Option (including
the Additional Target(s) that Omeros selects pursuant to Section 2.2.b, if any, or this
Section 2.2.d), North Coast fails to deliver either the First Due Date Deliverables by
the First Due Date specified in any of such Additional Target Research Plans or the
Second Due Date Deliverables by the Second Due Date

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

7

 

	 	 	 	specified in such Additional Target
Research Plan, then within thirty (30) days of receipt from Omeros of a written demand
therefor, [†].

	2.3	 	Additional Services and Deliverables. North Coast and Omeros may mutually agree that
additional Services not envisioned by the Initial Research Plan or an Additional Target
Research Plan (if any) will be provided under this Agreement, which shall be specified in one
or more additional research plans, including all additional Deliverables, any additional fee
compensation payable and a timeline for performance, the Initial Research Plan, any Additional
Target Research Plan and any additional research plans each referred to herein as a “Research
Plan.”
	 
	2.4	 	Failure to Provide Services and Deliverables by Due Date and Replacement Target. If North
Coast fails to deliver to Omeros either the First Due Date Deliverables by within [†] of the
First Due Date specified in the Initial Research Plan or any Additional Target Research Plan
(as applicable) or the Second Due Date Deliverables by within [†] of the Second Due Date
specified in such Initial Research Plan or any Additional Target Research Plan (as applicable), then Omeros in its sole discretion may: (a) terminate the
Research Plan upon written notice to North Coast; provided, however, that if at any time
after such [†] Omeros has not terminated the Research Plan and North Coast provides Omeros a
humanized Lead Candidate that meets the Acceptance Criteria and the related Services and
Deliverables under the Research Plan, then Omeros may not terminate such Research Plan
pursuant to this Section 2.4; and/or (b) select an Additional Target, in which case the
Parties will enter into an Additional Target Research Plan for such Additional Target on the
terms and conditions set forth in Section 2.2.a, except that (i) Omeros will not be required
to pay a Subsequent Access Fee with respect to such Additional Target, (ii) Omeros will not
be required to pay an Additional Target Antibody cDNA Fee with respect to the humanized Lead
Candidate generated under such Additional Target Research Plan and (iii) such Additional
Target will not be counted for purpose of determining how many remaining Additional Targets
are subject to the Option under Section 2.2.a.
	 
	 	 	If Omeros is entitled under Section 2.4(a) to terminate a Research Plan but has not done so,
then until it has exercised its right to terminate the Research Plan (1) North Coast will
continue providing the Services and Deliverables described in the Research Plan and (2) North
Coast and Omeros will communicate at least monthly to discuss any progress made by North Coast
under the Research Plan and Omeros’ continued interest in having North Coast continue work
under such Research Plan. If Omeros terminates a Research Plan in accordance with this
Section 2.4, Omeros shall have no further obligations to North Coast with respect to any
Services or Deliverables provided under such Research Plan (including, without limitation, any
obligation to pay any fees in connection with such Research Plan such as Development Milestone
Payments or Sales Royalties under Section 3).
	 
	2.5	 	Best Efforts. North Coast shall use its continuing best efforts to diligently complete all
Services, to deliver all Deliverables and meet all milestones set forth in all Research Plans
within the timeline set forth within the applicable Research Plans, and to achieve the Overall
Objective, and shall ensure that all Services are carried out and Deliverables

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

8

 

	 	 	generated and
developed using staff that are fully qualified and in accordance with the prevailing
professional standards of the industry.
	 
	2.6	 	Subcontracting. North Coast shall not subcontract with any other entity for the performance
of any portion of the Services or for the provision of any Deliverables without Omeros’
express written consent. Any approval of a subcontract by Omeros does not grant the right to
any approved subcontractor to further subcontract its obligations without first obtaining
further express prior written consent of Omeros. Any approved subcontractor shall be subject
to all of the terms applicable to the North Coast under this Agreement, provided that North
Coast shall be responsible and remain liable for the performance of all obligations of North
Coast under this Agreement and any breach thereof by any subcontractor.
	 
	2.7	 	Compliance with Laws. North Coast shall comply with all applicable international, national,
county and local laws, rules and regulations in providing the Services and delivering the
Deliverables. North Coast shall promptly notify Omeros if any regulatory agency takes action
against North Coast for any defect or deficiency, during the Term (as defined in Section 8.1)
of this Agreement, or if any other adverse event occurs that
materially limits North Coast’s ability to complete the Services and provide the
Deliverables.
	 
	2.8	 	Transfer of Antibodies. North Coast shall assist Omeros and cooperate with transfer of the
Chimeric Antibodies, Lead Candidates, Second Generation Candidates and Optional Candidates,
their respective physical cDNA’s, cDNA sequences in written and electronic form, antibody
expression constructs and antibody expressing cell lines, as applicable, as well as the
respective Records and Materials (as defined in Section 4.1.b) in physical and electronic
form, to third party(ies) designated by Omeros for further development and/or manufacture of
preclinical, clinical and commercial supplies of North Coast-Originated Antibodies.
	 
	3	 	Payments and Royalties
	 
	3.1	 	Payment Terms. As full and complete consideration for the Services and Deliverables, all
licenses, intellectual property and other rights conveyed, and all obligations undertaken in
accordance with this Agreement, Omeros shall pay North Coast the amounts set forth in this
Section 3 upon satisfaction of the respective conditions for each payment. Any portion of the
Services that reasonably need to be reperformed, or any Deliverables that reasonably need to
be reproduced, due to no fault of Omeros shall be promptly reperformed or reproduced, if
requested by Omeros, without added charge.

	 	a)	 	Technology Access Fees.
	 
	 	 	 	3.1.a.1 Initial Access Fee. Omeros shall pay North Coast a fee of [†] (the “Initial
Access Fee”) on invoice to be submitted upon execution of this Agreement for access rights
to North Coast’s Pre-existing Intellectual Property and the New North Coast Intellectual
Property (as such terms are defined in Sections 7.1 and 7.2.a,

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

9

 

	 	 	 	respectively) to be used by
North Coast for Omeros’ benefit in performing the Services described under the Initial
Research Plan and any other Research Plans covering Additional Targets for which Omeros
exercises its Option prior to [†], and to permit Omeros to use, develop, commercialize,
sell and distribute the Deliverables provided under the Initial Research Plan and any such
other Research Plans. North Coast acknowledges receipt from Omeros on October 10, 2008 of
[†] as partial payment towards the Initial Access Fee, and agrees that the invoice for the
Initial Access Fee shall show a credit to Omeros for such amount and the total amount
owing to North Coast for the Initial Access Fee shall be [†]. The Initial Access Fee is
payable by Omeros only one time regardless of how many such Research Plans Omeros and
North Coast enter into, and regardless of how many antibodies North Coast generates
against MASP-2 and any Additional Targets.
	 
	 	 	 	3.1.a.2 Subsequent Access Fees. Subject to the terms and conditions of this
Agreement, if at any time after [†] (a) Omeros exercises its Option for an Additional
Target and (b) such exercise is the first exercise by Omeros of its Option for any
Additional Target during the then-current calendar year, then Omeros shall pay North Coast
a fee (a “Subsequent Access Fee”) on invoice, to be submitted upon mutual execution of the
Additional Target Research Plan for such Additional Target, for access rights to North
Coast’s Pre-existing Intellectual Property and the New North Coast
Intellectual Property to be used by North Coast for Omeros’ benefit in performing the
Services described under such Additional Target Research Plan and any other Research Plans
covering Additional Targets for which Omeros exercises its Option during such calendar
year, and to permit Omeros to use, develop, commercialize, sell and distribute the
Deliverables provided under such Additional Target Research Plan and any other such
Research Plans. A Subsequent Access Fee is payable by Omeros only one time during such
calendar year, regardless of how many Additional Targets Omeros’ exercises its Option for
during a calendar year, and regardless of how many antibodies North Coast generates
against any Additional Targets during such calendar year. The Subsequent Access Fee shall
be:

	 	 	 	3.1.a.2.1 [†] for the first calendar year after [†] in which Omeros exercises its
Option (“Calendar Year I”),
	 
	 	 	 	3.1.a.2.2 [†] for the first calendar year after Calendar Year I in which Omeros
exercises its Option (“Calendar Year II”), and
	 
	 	 	 	3.1.a.2.3 [†] for the first calendar year after Calendar Year II in which Omeros
exercises its Option (“Calendar Year III”).

	 	 	 	For purposes clarification, Calendar Year I can be any calendar year during the Option
Period beginning with calendar year [†], and Calendar Year I, Calendar Year II and Calendar
Year III do not have to be successive calendar years. Notwithstanding anything in this
Agreement to the contrary, Omeros shall not be required to pay a technology access fee
(including any Subsequent Access Fees) with respect to any Additional

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

10

 

	 	 	 	Targets for which
Omeros exercises its Option after Calendar Year III; provided that in consideration of
Omeros’ agreement to pay the Subsequent Access Fees during Calendar Year I, Calendar Year II
and Calendar Year III, North Coast shall grant access rights to North Coast’s Pre-existing
Intellectual Property and the New North Coast Intellectual Property to be used by North
Coast for Omeros’ benefit in performing the Services described under any Research Plans
covering Additional Targets for which Omeros exercises its Option after Calendar Year III,
and permit Omeros to use, develop, commercialize, sell and distribute the Deliverables
provided under such Research Plans.

	 	b)	 	cDNA Fees.

	 	 	 	3.1.b.1 MASP-2 cDNA Fee. If, after North Coast provides all of the Services and
Deliverables described in Section 2.3(a) of the Initial Research Plan with respect to [†],
then on invoice Omeros shall pay to North Coast a one-time fee of [†].
	 
	 	 	 	3.1.b.2 Optional MASP-2 Candidate cDNA Fee. If at Omeros’ written request North
Coast generates a [†], and after North Coast provides all of the Deliverables described in
Section 2.3(a) of the Initial Research Plan with respect to [†], then on invoice Omeros
shall pay to North Coast a one-time fee of [†] (the “Optional MASP-2 Candidate cDNA Fee”).
Omeros shall pay North Coast an Optional MASP-2 Candidate cDNA Fee for each [†] and for
which North Coast has provided the Deliverables described in Section 2.3(a).
	 
	 	 	 	3.1.b.3 Additional Target Antibody cDNA Fee. For each Additional Target, if after
North Coast provides all of the applicable Services and Deliverables described in the
applicable Additional Target Research Plan with respect to the applicable [†], then on
invoice Omeros shall pay to North Coast a one-time fee of [†] (the “Additional Target
Antibody cDNA Fee”); provided, however, that Omeros and North Coast may agree at the time
of execution of the applicable Additional Target Research Plan [†].
	 
	 	 	 	3.1.b.4 Optional Additional Target Antibody cDNA Fee. If at Omeros’ written request
North Coast generates a [†] under an Additional Target Research Plan, and after North
Coast provides all of the Services and Deliverables described in the Additional Target
Research Plan with respect to [†], then on invoice Omeros shall pay to North Coast a
one-time fee of [†] (the “Optional Additional Target Antibody cDNA Fee”). Omeros shall
pay North Coast an Optional Additional Target Antibody cDNA Fee for each such humanized
Optional Candidate requested by Omeros that [†].

	 	c)	 	Additional Services and Deliverables. Fees for any additional Services and Deliverables
not envisioned by this Agreement shall be as set forth in any amendments to this Agreement
and shall be determined on a per project basis.
	 
	 	d)	 	Development Milestone Payments. For each Omeros Therapeutic, Omeros shall pay North Coast
the following one-time development milestone payments (each a “Development Milestone
Payment”) on invoice upon completion of the associated development activity (each a
“Development Milestone”) by Omeros or by a licensee of

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

11

 

	 	 	 	Omeros for an Omeros Therapeutic.
Omeros shall provide North Coast written notice of the completion of each Development
Milestone by Omeros or Omeros’ licensee within thirty (30) days of such Development Milestone
completion. The Development Milestone Payments that may become due for an Omeros Therapeutic
shall be [†], as set forth in the following table:

	 	 	 	 	 	 	 	 	 	 	 
	Development Milestone	 	Development Milestone Payment [†] for the Omeros Therapeutic [†]:
	 	 	 	 	Each no later	 	Each no later	 	Each no later	 	 
	 	 	Each by the [†]	than [†] set	than [†] set	 	than [†] set	Each at least [†]
	 	 	set forth in	 	forth in	 	forth in	 	forth in	 	set forth in
	 	 	applicable	 	applicable	 	applicable	 	applicable	 	applicable
	 	 	Research Plan	 	Research Plan	 	Research Plan	 	Research Plan	 	Research Plan*
	 
	 	 	 	 	 	 	 	 	 	 
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	 	[†]

 

			
	*	 	Humanized Lead Candidate must meet applicable Acceptance Criteria [†].

	 	e)	 	Royalties. For each Omeros Therapeutic, Omeros shall pay North Coast a royalty as a
percentage of Net Sales of such Omeros Therapeutic (the “Sales Royalty”). The applicable
Sales Royalty rate that may become due for an Omeros Therapeutic shall be [†], as set forth
in the following table:

	 	 	 	 	 	 	 
	Sales Royalty rate [†] for the Omeros Therapeutic [†]:
	 	 	Each no later than [†] set	 	Each no later than [†] set	 	Each no later than [†] set
	Each by the [†] set forth in	 	forth in applicable	 	forth in applicable	 	forth in applicable
	applicable Research Plan	 	Research Plan	 	Research Plan	 	Research Plan
	[†]

	 	[†]
	 	[†]
	 	[†]

	 	 	 	Sales Royalties shall be paid on a [†] within [†] following the end of each [†] for Net Sales
realized during such [†]. Notwithstanding anything above in this Section 3.1.e, Omeros shall
not be required to pay North Coast a Sales Royalty for Net Sales on a MASP-2 Therapeutic or
an Additional Target Therapeutic realized during any period in a country or territory in
which a third party, without license or other authority from Omeros, also sells or
distributes a MASP-2 therapeutic or an Additional Target therapeutic, respectively, that
infringes one or more claims of the Omeros Antibody Patents, provided that Omeros has acted
with reasonable diligence in seeking to enforce the applicable Omeros Antibody Patents to
enjoin such third party sales or distribution after discovery by Omeros of such third party
sales or distribution.

	3.2	 	Price Adjustments for Additional Targets. The Additional Target Antibody cDNA Fee, Optional
Additional Target Antibody cDNA Fee and each Development Milestone Payment (collectively
“Fees”) shall remain fixed for all Additional Targets for which

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

12

 

	 	 	Omeros exercises its Option on
or before [†]. For any Additional Targets for which Omeros exercises its Option after [†],
the Fees will each be increased each year by the lesser of (a) [†] and (b) the seasonally
adjusted change in the Producer Price Index for pharmaceutical and medicine manufacturing
(commodity code 32541) issued by the Bureau of Labor Statistics, U.S. Department of Labor
(“PPI”) for the year ending immediately preceeding the year in which the Option is exercised.
For example, if Omeros exercises its Option for an Additional Target in [†], the Fees will be
increased over the Fees payable in [†] by the lesser of [†] and the PPI for [†]. For an
antibody requested in [†], the Fees will be increased over the Fees payable in [†] by (1) the
lesser of [†] and the PPI for [†] and (b) the lesser of [†] or the PPI for [†]. No other
payments that may become due hereunder, including without limitation the Subsequent Access
Fees and Sales Royalty rates, will be subject to increase pursuant to this Section 3.2.

	3.3	 	Invoices. North Coast shall submit invoices to Omeros for payments, other than Sales
Royalties that have become due. The terms of payment are [†] after Omeros’ receipt of North
Coast’s invoice, or in the event that any invoice is disputed in good faith, [†] after mutual
agreement or other resolution is reached on the disputed invoice or receipt of a corrected
invoice. Invoices shall reference this Agreement and the relevant Research Plan (as
applicable) and specify the milestone payment or other fee that is being invoiced. Payment for
Sales Royalties shall be made by Omeros concurrent with delivery of the Net Sales reports
specified in Section 4.1.a.
	 
	 	 	Invoices shall be sent to Omeros by mail addressed to the following or subsequently updated
address:

	 	 	 
	 

	 	Accounts Payable
	 

	 	Omeros Corporation
	 

	 	1420 Fifth Avenue, Suite 2600
	 

	 	Seattle, WA 98101

	 	 	North Coast shall provide and keep Omeros updated on invoice payment instructions, including
wire transfer information or the payee and address for checks.
	 
	3.4	 	Obligation to Pay Taxes. Payments under this Agreement shall be made in full in the agreed
amounts without deduction for taxes of any kind whatsoever. Any taxes that may be due and
payable as a result of Omeros’ payments under this Agreement are solely North Coast’s
responsibility.
	 
	4	 	Reports; Records; Audits; Inspections
	 
	4.1	 	Reports and Record Maintenance.
	 
		 	a) By Omeros. Following the initial approval by a Regulatory Agency for the sale by Omeros
or a licensee of Omeros of an Omeros Therapeutic, Omeros shall provide North Coast with a Net
Sales report on a [†] setting forth the quantity of sales of such Omeros Therapeutic, the
gross monetary amounts invoiced and collected by either Omeros or by a licensee of Omeros
(and reported to Omeros during such [†]) for the initial distribution or

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

13

 

	 	 	sale of such Omeros
Therapeutic, and the total of all deductions provided for in Section 1.9 during such [†],
within [†] following the end of each [†] for Net Sales realized during such [†].
	 
		 	b) By North Coast. North Coast shall provide Omeros written status reports regarding its
progress on all uncompleted Research Plans on an at least [†] commencing [†], with each
report due within [†] of the end of the preceding [†]. North Coast shall maintain complete
and accurate written and electronic records, accounts, notes, reports and data, and
materials, including, without limitation, B cell cultures, culture supernatants, sequence
information, expression construct DNA and viable clones of all Chimeric Antibodies, Lead
Candidates, Optional Candidates and Second Generation Candidates (as applicable) and any
other records and materials listed in Section 2.8, relating to its performance of the
Research Plans (the “Records and Materials”) for the longer of the following minimum periods:
(i) all Records and Materials related to North Coast-Originated Antibodies or Omeros
Therapeutics approved by FDA for marketing shall be retained by North Coast for at least two
(2) years after such FDA approval; (ii) all Records and Materials related to North
Coast-Originated Antibodies or Omeros Therapeutics for which Omeros submits an IND will be
retained by North Coast for at least five (5) years after such submission; and (iii) all
records related to North Coast-Originated Antibodies or Omeros Therapeutics for which Omeros
notifies North Coast that an IND has not been filed and is not planned to be filed shall be
retained by North Coast for at least [†] following North Coast receipt of notice of such
determination from Omeros. North Coast shall notify Omeros at least [†] before any Records
and Materials are to be disposed of or destroyed. If at any time Omeros requests receipt of
all or any portion of the original Records and Materials, North Coast shall send such
original Records and Materials to Omeros at Omeros’ reasonable expense.
	 
	4.2	 	Audit of Omeros Books. North Coast shall have the right to employ a certified public
accountant to review and reconcile the directly relevant accounting records and procedures of
Omeros solely as they relate to the determination of Sales Royalties, during reasonable
business hours and no more than [†] a year, and Omeros agrees to make available at Omeros’
place of business all such directly relevant accounting records for that purpose within [†]
of written request by North Coast. The cost of such review shall be borne by North Coast,
unless it is found that Omeros under-paid a [†] Sales Royalty for any [†] by an amount of [†]
or greater, in which case the cost of such review shall be borne by Omeros.
	 
	4.3	 	Visits, Audits and Inspections. Omeros’ representatives may visit North Coast’s facilities
at reasonable times and with reasonable frequency during normal business hours to observe the
progress of the Services and Deliverables under any Research Plan, within [†] of written
request. North Coast shall assist Omeros in scheduling and implementing such visits. During
the visits, Omeros representatives may examine all Records and Materials, facilities and
equipment that pertain to any Services and Deliverables, and any other relevant resources
pertaining to any Research Plan, as well as any other audit reports prepared by or on behalf
of North Coast with respect to quality audits of such relevant

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

14

 

	 	 	resources. If North Coast
receives a request from any Regulatory Agency to inspect any portion of North Coast’s
facilities related to the performance of any Services and Deliverables, North Coast shall
notify Omeros in advance and provide Omeros an opportunity, at Omeros’ expense, to participate
in such inspection, and shall fully inform Omeros of the results of such inspection.
	 
	5	 	Samples
	 
	5.1	 	Use of Samples. Omeros shall transfer to North Coast the sufficient or requested quantities
of proteins, reagents, antibodies and/or other materials involved in the Services as specified
in any Research Plan (“Samples”). Omeros shall provide all pertinent information known to
Omeros regarding the Samples to the extent necessary for carrying out any Research Plan. North
Coast shall be responsible for and bear the expense of obtaining any other chemicals,
materials, equipment, animals and facilities needed to conduct the Services and produce the
Deliverables. North Coast shall not use or analyze any Samples provided under this Agreement
except as necessary to carry out the relevant Research Plan and shall not administer or permit
the Samples to be administered to any person. After completion of the Services, North Coast
shall either return the Samples to Omeros or dispose of the Samples, upon written request by
Omeros and at Omeros’ risk and expense. North Coast accepts full responsibility for safe
handling of all Samples or other compounds or materials used in the performance of the
Services and shall be responsible for any loss or destruction of the Samples after delivery to
North Coast.
	 
	5.2	 	Ownership of Samples. The Samples are and shall remain the sole property of Omeros and
nothing in this Agreement shall be construed as granting to North Coast, by implication or
otherwise, any right or license with respect to the Samples, or any patent or other
intellectual property rights with respect to the Samples, except as required to complete the
Services and generate the Deliverables, and North Coast shall not file applications or
otherwise seek any proprietary rights in respect of the Samples or any Confidential
Information (as that term is defined in Section 6.1) that Omeros provides under this
Agreement.
	 
	6	 	Confidentiality and Non-use
	 
	6.1	 	As used in this Agreement, “Confidential Information” shall mean any Samples, other
materials, data, research, development, manufacturing, marketing, financial, personnel, sales,
business, and other non-public, proprietary or technical information provided by a disclosing
Party (the “Disclosing Party”) to a receiving Party (the “Recipient”), including, without
limitation, all Deliverables, Records and Materials (which shall be considered Omeros’
Confidential Information even if generated or provided by North Coast), except any portion of
such information that the Recipient establishes:
	 
	 	 	a) is or becomes generally available to the public or within the industry to which such
information relates, other than as a result of a breach of this Agreement; or
	 
	 	 	b) is known by Recipient at the time of receipt of the Disclosing Party’s information, as
evidenced by Recipient’s contemporaneous written records; or

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

15

 

	 	 	c) is provided to Recipient on a non-confidential basis by a third party who has the legal
right to make such disclosure; or
	 
	 	 	d) was or is independently developed by or for Recipient without access to or use of the
information of the Disclosing Party, as evidenced by Recipient’s contemporaneous written
records.
	 
	6.2	 	Obligations of Confidentiality and Non-use. Each Party agrees that the Disclosing Party has
and shall retain sole and exclusive rights of ownership of all Confidential Information
disclosed or owned by such Party. Each Recipient agrees that during the Term of this Agreement
and for [†] thereafter it will not use any Confidential Information of the Disclosing Party
except for the purposes of performing under this Agreement, unless otherwise agreed by the
Parties in writing. Each Recipient agrees not to disclose any Confidential Information of the
Disclosing Party to others (except to Recipient’s employees, consultants, professional
advisors, agents and Affiliates who reasonably require disclosure of such Confidential
Information to achieve the purposes of this Agreement and who are bound to the Recipient by
like obligations as to confidentiality and non-use no less stringent than those set forth
herein) during the Term of this Agreement and for [†] thereafter without the prior written
consent of the Disclosing Party. North Coast agrees that with respect to the Records and
Materials, which are included in Omeros’ Confidential Information, these obligations of
non-use and confidentiality shall subsist beyond [†] after the termination of this Agreement.
Each Party agrees to maintain and follow reasonable procedures to prevent unauthorized
disclosure or use of the other Party’s Confidential Information and to prevent it from
becoming disclosed or being accessed by unauthorized persons. Each Party agrees that it may
disclose to authorized persons only such Confidential Information of the Disclosing Party as
is necessary for each such authorized person to perform his/her responsibilities under this
Agreement. Recipient shall advise the Disclosing Party of any disclosure, loss, or use of
Confidential Information of the Disclosing Party in violation of this Agreement as soon as
practicable. Each Party agrees to return or destroy the Confidential Information of the other
Party, whether in written, graphic, electronic or other tangible form, upon written request,
provided, however, that legal counsel for each Party may retain an archival copy of
Confidential Information solely for purposes of ensuring compliance with this Agreement.
	 
	6.3	 	Disclosure of this Agreement. The terms of this Agreement shall be considered each Party’s
Confidential Information, and accordingly except for disclosures expressly permitted under
this Agreement, neither Party may release any information to any third party regarding the
terms of this Agreement without the prior written consent of the other Party. Notwithstanding
the foregoing, the terms of this Agreement may be disclosed by either party to its existing or
potential investors, acquirers, merger partners, commercial partners, shareholders, directors,
officers and professional advisors as long as such individuals or entities are subject to
similar conditions of confidentiality.
	 
	6.4	 	Permitted Disclosures. Notwithstanding anything to the contrary, a Party may disclose
Confidential Information of the other Party, including, without limitation, the terms of this

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

16

 

	 	 	Agreement, to the extent such disclosure is reasonably necessary: (a) to secure patent
protection for an Intellectual Property Right developed pursuant to this Agreement consistent
with the ownership provisions set forth in Section 7; (b) to comply with applicable laws or
regulations, the requirements of any Regulatory Agency or other regulatory or governmental
authority, including, without limitation, FDA, the US Securities and Exchange Commission, the
Federal Trade Commission and/or the Department of Justice, or judicial order from a court of
competent jurisdiction; or (c) as necessary for Omeros to conduct pre-clinical studies,
clinical trials, achieve the Overall Objective or to seek regulatory approval to market Omeros
Therapeutics. Prior to making any such permitted disclosures, however, the Recipient shall
give reasonable advance notice to the Disclosing Party with as much detail as possible in
relation to the disclosure. Each Party agrees that it shall cooperate fully and in a timely
manner with the other Party with respect to all such permitted disclosures, including
determining what information should be released and requests for confidential treatment of
Confidential Information of either Party included in any such disclosure where possible;
provided that in no event shall a Party be required to delay any filing or release
unreasonably hereunder.
	 
	6.5	 	Remedies. Because of the unique nature of the Confidential Information, each Recipient
acknowledges and agrees that the Disclosing Party may suffer irreparable injury if the
Recipient fails to comply with the obligations set forth in this Section 6, and that monetary
damages may be inadequate to compensate the Disclosing Party for such breach. Accordingly,
each Recipient agrees that the Disclosing Party will, in addition to any other remedies
available to it at law, in equity or otherwise, without the requirement to post a bond, be
entitled to seek injunctive relief and/or specific performance to enforce the terms, or
prevent or remedy the violation, of this Section 6. This provision shall not constitute a
waiver by either Party of any rights to damages or other remedies which it may have pursuant
to this Agreement or otherwise.
	 
	7	 	Intellectual Property; Licenses
	 
	7.1	 	Pre-existing Intellectual Property. Except as expressly provided in this Section 7, neither
Party shall, as a result of this Agreement, acquire any right, title, or interest in any
Intellectual Property Rights that the other Party owned, licensed or controlled as of the
Effective Date of, or that the other Party obtains ownership, license or control of separate
and apart from the performance of, this Agreement (each Party’s “Pre-existing Intellectual
Property”).
	 
	7.2	 	New Intellectual Property

a) Except as expressly provided in Section 7.3, North Coast shall own all right, title and
interest in “New North Coast Intellectual Property”, which shall mean Intellectual Property
Rights that North Coast develops, conceives, invents, reduces to practice or makes in the
course of performance under this Agreement that consists of subject matter of general
applicability to the current business of North Coast or therapeutic target other than MASP-2
and any Additional Target for which North Coast and Omeros enter into a

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

17

 

Research Plan (MASP-2 and any such Additional Targets collectively, the “Omeros Targets” and
each individually, an “Omeros Target”) and that is not specific to, and only to the extent
that it does not apply to: any of the Omeros Targets; any inhibitor of an Omeros Target; any
Omeros Target antibody or antibody fragment that binds to Omeros Target polypeptides or
portions thereof, including, without limitation, North Coast-Originated Antibodies; any
pharmaceutical or biological therapeutic for the inhibition of an Omeros Target, including,
without limitation, any Omeros Therapeutic; any method or process for generating or producing
any Omeros Target antibody or antibody fragment that binds to Omeros Target polypeptides or
portions thereof, including, without limitation, North Coast-Originated Antibodies; any
process or method for generating or producing Omeros Therapeutics; and any method of
treatment by inhibiting an Omeros Target.

b) Omeros shall own all right, title, and interest in (a) the Omeros Antibody Patents, (b)
all Intellectual Property Rights that either Party, solely or jointly with others, develops,
conceives, invents, reduces to practice, improves, or makes in the course of performance
under this Agreement that is directed or specific to: an Omeros Target; any inhibitor of an
Omeros Target; any Omeros Target antibody or antibody fragment that binds to Omeros Target
polypeptides or portions thereof, including, without limitation, North Coast-Originated
Antibodies; any pharmaceutical or biological therapeutic for the inhibition of an Omeros
Target, including, without limitation, any Omeros Therapeutic; any method or process for
generating or producing any Omeros Target antibody or antibody fragment that binds to Omeros
Target polypeptides or portions thereof, including, without limitation, North
Coast-Originated Antibodies; any process or method for generating or producing Omeros
Therapeutics; and any method of treatment by inhibiting an Omeros Target, and (c) any and all
other Intellectual Property Rights, excluding the New North Coast Intellectual Property, and
other work product generated by either Party during the course of performance under this
Agreement, including, without limitation, all Intellectual Property Rights embodied or
documented in the Records and the Materials, (collectively, the “New Omeros Intellectual
Property”). North Coast hereby assigns, and shall continue to assign to Omeros, all of North
Coast’s right, title and interest in any New Omeros Intellectual Property. North Coast shall
promptly disclose to Omeros in writing all New Omeros Intellectual Property. North Coast
shall execute, and shall require North Coast’s personnel involved in the performance of the
Services to execute, any documents required to confirm Omeros’ ownership of the New Omeros
Intellectual Property, and any documents required to apply for, maintain and enforce any
patents or other rights in the New Omeros Intellectual Property. Upon Omeros’ request and at
Omeros’ reasonable expense, and at no cost to North Coast, North Coast shall assist Omeros as
may be necessary to apply for, maintain and enforce any patents or other rights in the New
Omeros Intellectual Property.

	7.3	 	Grant of License. North Coast hereby grants Omeros a non-exclusive, fully paid-up,
irrevocable and transferable license, with the right to grant and authorize sublicenses, under
(a) all of North Coast’s Pre-existing Intellectual Property, and (b) all New North Coast
Intellectual Property, to the extent that North Coast’s Pre-existing Intellectual Property or
the New North Coast Intellectual Property is necessary, useful or beneficial to

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

18

 

	 	 	express, modify, formulate, manufacture,
test, develop, market, commercialize, make,
have made, use, sell, import, and distribute
any Deliverable called for in any Research
Plan, any North Coast-Originated Antibody and
any Omeros Therapeutic.
	 
	7.4	 	Field Exclusivity. [†].
	 
	8	 	 Term and Termination

	8.1	 	Term. The term of this Agreement begins on the Effective Date and, unless earlier terminated
as provided for below in this Section 8, continues in full force and effect until the later of
(a) North Coast’s satisfactory completion of all Services and delivery of all Deliverables
described in all Research Plans, (b) the expiration of the Option Period and (c) the point in
time at which there are no patent application(s) in the process of being prepared for filing,
no pending patent applications and no valid and enforceable claim included within any patent,
utility model or inventor’s certificate within (i) the Omeros Antibody Patents, (ii) North
Coast’s Pre-existing Intellectual Property that relates to any North Coast-Originated Antibody
or any Omeros Therapeutic and (iii) the New North Coast Intellectual Property that relates to
any North Coast-Originated Antibody or any Omeros Therapeutic (the “Term”).
	 
	8.2	 	Survival. The provisions of Sections 5-7, 8.2, 8.4, 9, 10 and 12-14 shall survive
termination of this Agreement.
	 
	8.3	 	Termination for Cause. Either Party may terminate this Agreement at any time in the event
that the other Party breaches any material obligation of this Agreement by first submitting
written notice of breach to the breaching Party, which breach is not substantially cured
within ninety (90) days of the receipt of such notice, followed by written notice of termination then being
sent to the breaching Party.
	 
	9	 	Representations and Warranties
	 
	9.1	 	Authority. Each Party represents and warrants that it has full power and authority to
execute, deliver and perform this Agreement, and that the terms of this Agreement do not
conflict with any other contractual agreement or obligation to which it is a Party.
	 
	9.2	 	Intellectual Property. North Coast represents and warrants that:

a) North Coast will provide all Services and deliver all Deliverables to Omeros free and
clear of any liens, encumbrances or claims of any third party;

b) North Coast’s provision of all Services for, and delivery of all Deliverables to, Omeros
in accordance with this Agreement and all Research Plans will not infringe, misappropriate,
violate or utilize any third party’s Intellectual Property Rights known to North Coast or
third party confidential information known to North Coast, and no North Coast employee will
violate any non-competition or similar agreements with any third party as a result of
providing the Services and Deliverables;

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

19

 

c) the pending patent applications listed on Exhibit D attached hereto (the “North
Coast Patents”) are owned by North Coast and included in North Coast’s Pre-existing
Intellectual Property, the claims of the North Coast Patents are patentable, and the claims
of the North Coast Patents read on the processes and systems North Coast shall utilize in the
performance of the Services and generation of the Deliverables under this Agreement and will
provide North Coast exclusivity with respect to performance of the Services and generation of
the Deliverables in the countries and regions in which the North Coast Patents were granted;

d) except with respect to any Intellectual Property Rights claiming methods or systems for
the host expression of antibodies or antibody fragments during clinical or commercial
manufacture, and except with respect to any Intellectual Property Rights that are specific to
MASP-2 or Additional Targets, Omeros’ use of the Deliverables to conduct research and
development and to generate, develop, produce and manufacture North Coast-Originated
Antibodies and Omeros Therapeutics, and the performance by Omeros of preclinical and clinical
development, manufacture, commercialization, distribution and sale of Omeros Therapeutics,
shall not infringe any third party’s Intellectual Property Rights known to North Coast.

	9.3	 	No Other Warranties. EXCEPT AS EXPRESSLY SET FORTH HEREIN, NEITHER PARTY MAKES ANY
REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY OF THE
IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, SAFETY, EFFICACY AND
NONINFRINGEMENT REGARDING THE SAMPLES, THE DELIVERABLES, THE NORTH COAST-ORIGNATED
ANTIBODIES, THE OMEROS THERAPEUTICS OR ANY OTHER SUBJECT MATTER OF THIS AGREEMENT.
	 
	10	 	Indemnification; Limitation of Liability
	 
	10.1	 	Indemnification. Each Party (the “Indemnifying Party”) shall indemnify, defend and hold
harmless the other Party, its affiliates, subsidiaries, officers, directors, employees,
consultants, and agents (collectively the “Indemnitees”) from any and all liability, loss
(including reasonable attorneys’ fees) or damage any of them may suffer as the result of
claims, demands, costs or judgments against them by unaffiliated third parties (collectively
“Claims”) that arise from the Indemnifying Party’s breach of any of its obligations,
representations, covenants and warranties under this Agreement, or the Indemnifying Party’s
negligent act or omission, willful misconduct or unlawful act, except and to the extent that
such Claims result from the breach by any Indemnitee of any of the Indemnitees’ obligations,
representations, covenants and warranties under this Agreement or any of the Indemnitees’
gross negligence, willful misconduct or unlawful act.
	 
	10.2	 	Procedure. In the event that any third party claim, action or suit is instituted against an
Indemnitee in respect of which indemnity may be sought pursuant to Section 10.1, the
Indemnitee will promptly notify the Indemnifying Party in writing (provided that the failure
to give such notice promptly will not prejudice the rights of an Indemnitee, except

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

20

 

	 	 	to the extent that the failure to give such prompt notice materially adversely affects the
ability of the Indemnifying Party to defend the claim, action or suit). Promptly after the
Indemnitee gives such written notice, the Indemnifying Party and the Indemnitee shall meet to
discuss how to respond to such claim, action or suit. The Indemnifying Party shall control
the defense of such claim, action or suit. The Indemnitee shall cooperate with the
Indemnifying Party in the defense of such claim, action or suit, at the expense of the
Indemnifying Party. In any such proceeding, the Indemnitee shall also have the right to
retain its own counsel at its own expense. The Indemnifying Party shall not be liable for
damages with respect to a claim, action or suit settled or compromised by the Indemnitee
without the Indemnifying Party’s prior written consent. No offer of settlement, settlement or
compromise by the Indemnifying Party shall be binding on an Indemnitee without the
Indemnitee’s prior written consent (which consent shall not be unreasonably withheld,
conditioned or delayed), unless such settlement fully releases the Indemnitee without any
liability, loss, cost or obligation to such Indemnitee, provided, however, that the
Indemnifying Party shall have no authority to take any action as part of any such defense or
settlement that invalidates or otherwise compromises or renders unenforceable any of the
Indemnitees’ Intellectual Property Rights without the Indemnitees’ express prior written
consent.
	 
	10.3	 	Limitation of Liability. Without limitation of any Party’s obligations to indemnify third
party Claims under Section 10.1, neither Party shall be liable for any indirect,
consequential, exemplary or incidental damages arising under or in association with this
Agreement, except for any such liability arising from fraud by the Party or from any breach of
the Party’s obligations regarding Confidential Information or Intellectual Property Rights
under this Agreement.
	 
	11	 	Insurance
	 
	 	 	Each Party will procure and maintain, at its own expense, for the duration of the Agreement,
and for [†] thereafter if written on a claims made or occurrence reported form, the types of
insurance specified below with carriers rated [†] with A. M. Best or like rating agencies, at
levels at all times commensurate with those standard in the industry for like companies at
like stages of development but in any event no less than the following levels:

(a) Workers’ Compensation in accordance with applicable statutory requirements and each Party
shall provide a waiver of subrogation in favor of the other Party;

(b) Employer’s Liability with a limit of liability in an amount of not less than [†];

(c) Commercial General Liability including premises operations, products & completed
operations, blanket contractual liability, personal injury and advertising injury including
fire legal liability for bodily injury and property damage in an amount not less than [†] per
occurrence and [†] in the aggregate;

(d) Products Liability in an amount not less than [†] each occurrence prior to Omeros’
initial administration of an antibody developed under this Agreement to humans as part of a
clinical trial cleared by FDA or other regulatory agency (“Initial Dosing”) and

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

21

 

of not less that [†] each occurrence after Initial Dosing, provided that Omeros shall
promptly notify North Coast upon Initial Dosing; and

(e) Excess Liability of [†] over Commercial General Liability and Employer’s Liability.

Each Party shall include the other Party and their subsidiaries, affiliates, directors,
officers, employees and agents as additional insureds with respect to Commercial General
Liability and Excess Liability. Each Party shall make available to the other Party, at such
other Party’s request, evidence of its maintenance of insurance in satisfaction of its
obligations under this Section 11. In the case of cancellation, non-renewal or material
change in said coverage, each Party shall promptly provide to the other Party with a new
certificate of insurance evidencing that the coverage meets the requirements in this Section
11. Each Party agrees that its insurance shall act as primary and noncontributory from any
other valid and collectible insurance maintained by the other Party. Each Party may, at its
option, satisfy, in whole or in part, its obligation under this Section 11 through its
self-insurance program.

	12	 	Use of Names
	 
	 	 	Except as may be required by law or regulation after first providing reasonable advance notice
to the other Party, neither Party may use the other Party’s name in any promotional,
advertising or other materials without the prior written consent of the other Party. North
Coast hereby consents to Omeros’ disclosure of North Coast’s name in connection with the
provision of the Services and the Deliverables under this Agreement to Omeros’ current and
potential employees, consultants, directors, shareholders, investors and partners, and to any
Regulatory Agency or other regulatory authority including, without limitation, FDA and the US
Securities and Exchange Commission.
	 
	13	 	Notices
	 
	 	 	Any notice required or permitted to be given hereunder by either Party shall be in writing
and shall be (a) delivered personally, (b) sent by registered mail, return receipt requested,
postage prepaid, (c) sent by an internationally recognized courier service guaranteeing
next-day delivery, charges prepaid, or (d) delivered by facsimile (with the original promptly
sent by any of the foregoing manners) to the address or facsimile number of the other Party
set forth below, or at such other address as may from time to time be furnished by notice by
either Party. The effective date of any notice hereunder shall be the date of receipt by the
receiving Party.

	 	 	 	 	 
	 

	 	If to Omeros:
	 	If to North Coast:
	 
	 

	 	Omeros Corporation
	 	North Coast Biologics LLC
	 

	 	1420 Fifth Avenue
	 	2815 Eastlake Avenue East
	 

	 	Suite 2600
	 	#300 
	 

	 	Seattle, WA 98101
	 	Seattle, WA 98102

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

22

 

	 	 	 	 	 
	 

	 	Attention: CEO
	 	Attention: President
	 

	 	And copy to: General Counsel	 	 
	 
	 

	 	Fax: 206.676.5005
	 	Fax:
	 

	 	Phone: 206.676.5000
	 	Phone: 206.605.0106

	14	 	Miscellaneous
	 
	14.1	 	Integration. This Agreement including all Research Plans, appendices and exhibits attached
thereto or incorporated by reference therein constitutes the entire understanding of the
Parties hereto regarding the subject matter of this Agreement, and no other representation,
agreement, promise or undertaking altering, modifying, taking from or adding to the terms of
this Agreement shall have any effect unless the same is reduced to writing and duly executed
by the Parties hereto. In the event of any conflict between the main body of this Agreement
and any attachments thereto or documents incorporated by reference therein, the provisions of
the main body of this Agreement shall control. Without limiting the foregoing, upon execution
of this Agreement (a) the Mutual Confidentiality Agreement between the Parties dated as of
June 10, 2008 shall terminate, except that the Parties’ obligations with respect to each
other’s Confidential Information (as defined therein) disclosed prior to the date of this
Agreement shall remain subject to the terms and condition of such agreement and (b) the FMAT
Agreement between the Parties dated October 21, 2008 shall be terminated and of no further
force or effect.
	 
	14.2	 	No Waiver. Either Party’s failure to enforce any provision of this Agreement will not be
considered a waiver of future enforcement of that or any other provision.
	 
	14.3	 	Governing Law. The laws of the State of Washington, without regard to its conflict-of-laws
provisions, shall govern this Agreement, its interpretation and its enforcement, and any
disputes arising out of or related to this Agreement.
	 
	14.4	 	Arbitration. The Parties agree that, except as provided herein below, any claim or
controversy arising out of or relating to this Agreement or breach thereof shall be settled by
arbitration in King County in the State of Washington, in accordance with the commercial rules
of the American Arbitration Association by a panel of three arbitrators, one selected by each
Party and the third selected by the other two arbitrators. In any such arbitration proceeding,
judgment upon the award rendered by the arbitrator shall be final and binding upon the Parties
and may be entered by either Party in any court or forum of competent jurisdiction as provided
herein below. Notwithstanding the foregoing, both Parties agree that any claims or
controversies concerning the infringement, validity or enforceability of any Intellectual
Property Rights, or the actual or threatened disclosure or misuse of any Confidential
Information, may alternately be resolved by a civil action in the court of competent
jurisdiction specified in Section 14.5, and both Parties further agree that each shall retain
the right to seek injunctive relief in the court of competent jurisdiction specified in
Section 14.5 to prevent a breach, threatened breach or continuing breach of this Agreement
that would cause irreparable injury, including, without limitation, breaches

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

23

 

	 	 	of confidentiality, infringement of Intellectual Property Rights or breach of Section 7.4
(Field Exclusivity).

	14.5	 	Jurisdiction and Venue. Any civil action prosecuted or instituted by either Party as
permitted herein above with respect to any matters arising out of or related to this Agreement
shall be brought in either the United States District Court located in King County the State
of Washington (if federal subject matter jurisdiction therein lies) or the Superior Court for
King County in the State of Washington, and each Party hereby consents to the exclusive
jurisdiction and venue of such courts for such purposes.
	 
	14.6	 	Attorney’s Fees. In the event that it is necessary for either Party to take legal action to
enforce any of the terms, conditions or rights contained herein, or to defend any such action,
then the prevailing Party in such action shall be entitled to recover from the other Party all
reasonable attorneys fees, costs and expenses related to such legal action.
	 
	14.7	 	Severability. In the event that any portion of this Agreement is held invalid or
unenforceable by a court of law, that provision will be construed and reformed to permit
enforcement of the provision to the maximum extent permissible consistent with the Parties’
original intent, and if such construction is not possible, such provision shall be struck from
this Agreement, and the remainder of the Agreement shall remain in full force and effect as if
such provision had never been part of this Agreement.
	 
	14.8	 	Independent Contractors. For the purposes of this Agreement, the Parties hereto are
independent contractors, and nothing in this Agreement shall be construed to place them in the
relationship of partners, principal and agent, employer/employee or joint venturers. Except as
provided expressly herein, each Party agrees that it shall have no authority to bind or
obligate the other Party, nor shall any Party hold itself out as having such authority.
	 
	14.9	 	Force Majeure. Neither Party will be liable for failure or delay in performing any
obligation under this Agreement, or will be considered in breach of this Agreement, if such
failure or delay is due to a natural disaster or any cause reasonably beyond such Party’s
control, provided that such Party resumes performance as soon as possible following the end of
the event that caused such delay or failure of performance.
	 
	14.10	 	Assignment. Neither Party may assign this Agreement, or any obligation or right under this
Agreement, in whole or in part, without the other Party’s prior written consent, which consent
will not be unreasonably withheld. This Section shall not be construed in any way to limit
Omeros’ rights to grant, at Omeros’ sole discretion, sublicenses hereunder. Each Party hereby
consents to the other Party’s assignment of this Agreement in whole or in part to any
successor in interest of the assigning Party as part of a merger, acquisition, other change of
control or together with a sale, transfer or other conveyance of all or substantially all of
that part of the assigning Party’s assets that pertain to this Agreement. Each Party’s
obligations and rights under this Agreement will be binding upon and will inure to the benefit
of the Parties’ permitted successors and assignees.
	 
	14.11	 	Counterparts. This Agreement may be executed in one or more counterparts, each of

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

24

 

which will be considered an original, and all of which will constitute the same instrument.

This Agreement is accepted and acknowledged by each Party through the signature of its authorized
representative below:

	 	 	 	 	 	 	 	 	 
	NORTH COAST BIOLOGICS LLC	 	OMEROS CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 
	By: /s/ Johnny Stine
 

Name: Johnny Stine
	 	By:

Name:
	 	/s/ Gregory A. Demopulos
 

Gregory A. Demopulos, M.D.
	 	 
	 
	Title:

	 	President
	 	Title:
	 	Chairman & CEO	 	 
	 
	Facsimile:

	 	 	 	Facsimile:
	 	206 676 5005 	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

25

 

Exhibit A to

Omeros Corporation

AGREEMENT FOR ANTIBODY DEVELOPMENT SERVICES

LIST OF ADDITIONAL TARGETS

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

1

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

2

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

3

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

4

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

5

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

6

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

7

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

8

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

9

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

10

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

11

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

12

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 1

	 	 	 	 	 	 	 
	Target	 	mAb	 	TA	 	Indication
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

13

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 2

	 	 	 	 	 	 	 	 	 
	Target	 	POC Reagent	 	TA	 	Indication	 	Institution/Company
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

1

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 2

	 	 	 	 	 	 	 	 	 
	Target	 	POC Reagent	 	TA	 	Indication	 	Institution/Company
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]
	 	 	 	 	 	 	 	 
	[†]
	 	 	 	 	 	 	 	 
	[†]
	 	 	 	 	 	 	 	 
	[†]
	 	 	 	 	 	 	 	 
	[†]
	 	 	 	 	 	 	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

2

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 3

	 	 	 	 	 	 	 	 	 
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

1

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 3

	 	 	 	 	 	 	 	 	 
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

2

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 3

	 	 	 	 	 	 	 	 	 
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

3

 

NorthCoast-Omeros Development Agreement Exhibit A, Part 3

	 	 	 	 	 	 	 	 	 
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	[†]

	 	[†]
	 	[†]
	 	[†]
	 	[†]
	 
	[†]
	 	 	 	 	 	 	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

4 

 

Exhibit B to

Omeros Corporation

AGREEMENT FOR ANTIBODY DEVELOPMENT SERVICES

RESEARCH PLAN FOR ANTIBODIES TO MASP-2

     This Research Plan for Antibodies to MASP-2 is dated as of October 31, 2008 and is between
Omeros Corporation (“Omeros”) and North Coast Biologics LLC (“North Coast”) and constitutes the
“Initial Research Plan” under the Agreement for Antibody Development dated October 31, 2008 between
Omeros and North Coast (the “Development Agreement”). Capitalized terms used but not defined in
this Initial Research Plan shall have the meanings given to them in the Development Agreement.

Task 1 — [†]

Section 1.1

     (a) Description. [†].

     (b) Time to Complete. North Coast will complete the Services and provide the Deliverables to
Omeros as described in Section 1.1(a) [†].

Section 1.2

     (a) Description. [†].

     (b) Time to Complete. [†]. Omeros shall have no liability under this Section 1.2, provided
that until Omeros has performed the matters described in this Section 1.2, North Coast will be
excused from providing any Services or Deliverables that are directly dependent upon such
performance unless Omeros’ delay is caused by North Coast’s failure to timely provide any of the
Services and Deliverables called for in this Initial Research Plan.

Task 2 —[†]

Section 2.1

     (a) Description. [†].

     (b) Time to Complete. North Coast will complete the Services and provide the Deliverables to
Omeros as described in Section 2.1(a) 

within [†].

Section 2.2

     (a) Description. [†].

     (b) Time to Complete. [†]. Omeros shall have no liability under this Section 2.2, provided
that until Omeros has performed the matters described in this Section 2.2, North Coast will be
excused from providing any Services or Deliverables that are directly dependent upon such
performance and any deadlines for such Services and Deliverables shall be extended by the

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

number of additional days in excess of [†]; provided, however, that North Coast will not be
excused from providing any Services or Deliverables and no deadlines for any Services or
Deliverables shall be extended if Omeros’ delay is caused by North Coast’s failure to timely
provide any of the Services and Deliverables called for in this Initial Research Plan.

     [†].

Section 2.3

     (a) Description. [†].

     (b) Time to Complete. North Coast will complete the Services and provide the Deliverables to
Omeros as described in Section 2.3(a) within no longer than [†].

     (c) Additional Assistance. [†].

Section 2.4

     (a) Description. [†].

     (b) Time to Complete. Omeros intends to complete the testing described in Section 2.4(a)
within [†].

Section 2.5

     Due Dates for all Deliverables. North Coast shall deliver all Deliverables required by
Section 2.1 of this Initial Research Plan, including the delivery to Omeros of [†] (the “First Due
Date”) and all Deliverables required by Section 2.3 of this Initial Research Plan, including the
delivery to Omeros of the [†] (the “Second Due Date”), which First and Second Due Dates shall be
deemed prospectively to have been met only upon Omeros’ determination in accordance with Sections
2.3 and 2.4, respectively, after delivery of such Deliverables that at least one of the [†], which
First and Second Due Dates may be extended due to certain delays by Omeros as provided for in the
Development Agreement and in this Initial Research Plan.

Section 2.6

     (a) Description. [†].

     (b) Time to Complete. North Coast will complete the Services and provide the Deliverables
with respect to an Optional Candidate as described in Section 2.3 within [†].

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

2

 

     This Initial Research Plan is accepted and acknowledged by each Party through the signature of its
authorized representative below, and is effective as of the date first set forth above in this
Initial Research Plan.

	 	 	 	 	 	 	 	 	 
	NORTH COAST BIOLOGICS LLC	 	OMEROS CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 
	By: /s/ Johnny Stine
 

Name: Johnny Stine
	 	By:

Name:
	 	/s/ Gregory A. Demopulos
 

Gregory A. Demopulos, M.D.
	 	 
	 
	Title:

	 	President
	 	Title:
	 	Chairman & CEO	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

3

 

Exhibit C to

Omeros Corporation

AGREEMENT FOR ANTIBODY DEVELOPMENT SERVICES

FORM OF ADDITIONAL TARGET RESEARCH PLAN

RESEARCH PLAN FOR ANTIBODIES TO [ADDITIONAL TARGET]

     This Research Plan for Antibodies to [ADDITIONAL TARGET] is dated as of [XXXX] and is between
Omeros Corporation (“Omeros”) and North Coast Biologics LLC (“North Coast”) and constitutes an
“Additional Target Research Plan” under the Agreement for Antibody Development dated October 31,
2008 between Omeros and North Coast (the “Development Agreement”). Capitalized terms used but not
defined in this Additional Target Research Plan shall have the meanings given to them in the
Development Agreement.

Task 1 — [†]

Section 1.1

     (a) Description. [†].

     (b) Time to Complete. North Coast will complete the Services and provide the Deliverables to
Omeros as described in Section 1.1(a) by [MONTH/DAY/YEAR]. [†]

Section 1.2

     (a) Description. [†].

     (b) Time to Complete. [†] Omeros shall have no liability under this Section 1.2, provided
that until Omeros has performed the matters described in this Section 1.2, North Coast will be
excused from providing any Services or Deliverables that are directly dependent upon such
performance unless Omeros’ delay is caused by North Coast’s failure to timely provide any of the
Services and Deliverables called for in this Additional Target Research Plan. [†]

Task 2 — [†]

Section 2.1

     (a) Description. [†].

     (b) Time to Complete. North Coast will complete the Services and provide the Deliverables to
Omeros as described in Section 2.1(a) 

within [†].

Section 2.2

     (a) Description. [†].

     (b) Time to Complete. [†]. Omeros shall have no liability under this Section 2.2, provided
that until Omeros has performed the matters described in this Section 2.2, North Coast will be
excused from providing any Services or Deliverables that are directly dependent upon such
performance and any deadlines for such Services and Deliverables shall be extended by the

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

number of additional days in excess of [†]; provided, however, that North Coast will not be
excused from providing any Services or Deliverables and no deadlines for any Services or
Deliverables shall be extended if Omeros’ delay is caused by North Coast’s failure to timely
provide any of the Services and Deliverables called for in this Additional Target Research Plan.
[†].

     [†]

Section 2.3

     (a) Description. [†].

     (b) Time to Complete. North Coast will complete the Services and provide the Deliverables to
Omeros as described in Section 2.3(a) within no longer than [†].

     (c) Additional Assistance. [†].

Section 2.4

     (a) Description. [†].

     (b) Time to Complete. Omeros intends to complete the testing described in Section 2.4(a)
within [†].

Section 2.5

     Due Dates for all Deliverables. Due Dates for all Deliverables. North Coast shall deliver
all Deliverables required by Section 2.1 of this Additional Target Research Plan, including the
delivery to Omeros of the [†] (the “First Due Date”) and all Deliverables required by Section 2.3
of this Additional Target Research Plan, including the delivery to Omeros of the [†] (the “Second
Due Date”), which First and Second Due Dates shall be deemed prospectively to have been met only
upon Omeros’ determination in accordance with Sections 2.3 and 2.4, respectively, after delivery of
such Deliverables that at least one of the [†], which First and Second Due Dates may be extended
due to certain delays by Omeros as provided for in the Development Agreement and in this Additional
Target Research Plan. [†].

Section 2.6

     (a) Description. [†].

     (b) Time to Complete. North Coast will complete the Services and provide the Deliverables
with respect to an Optional Candidate as described in Section 2.3 within [†].

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

2

 

This Additional Target Research Plan is accepted and acknowledged by each Party through the
signature of its authorized representative below, and is effective as of the date first set forth
above in this Additional Target Research Plan.

	 	 	 	 	 	 	 	 	 
	NORTH COAST BIOLOGICS LLC	 	OMEROS CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 	 	 
	 
	Name:

	 	 	 	Name:
	 	 	 	 
	 

	 	 

	 	 	 	 

	 	 
	Title:

	 	 	 	Title:	 	 	 	 
	 

	 	 

	 	 	 	 

	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

3

 

Exhibit D to

Omeros Corporation

AGREEMENT FOR ANTIBODY DEVELOPMENT SERVICES

LIST OF NORTH COAST PATENTS

Application No. [†]

Title: DISCOVERY AND GENERATION OF HIGH AFFINITY, FUNCTIONAL THERAPEUTIC OR DIAGNOSTIC PROTEINS

Filing Date: [†]

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSIONexv10w47

Exhibit 10.47

PATENT ASSIGNMENT AGREEMENT

     This agreement (the “Agreement”) is made effective the 23rd day of February 2009
(the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal
place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Roberto
Ciccocioppo, Ph.D., having a residence at Vicolo San Silvestro n. 25, Camerino, 62032 IT (“Dr.
Ciccocioppo”).

     WHEREAS Dr. Ciccocioppo owns all rights to certain technology invented by
Dr. Ciccocioppo related to new uses of peroxisome proliferator-activated receptor gamma
(“PPARg”) agonists; and

     WHEREAS Omeros has provided services for and funded the expenses of filing patent applications
for Dr. Ciccocioppo’ PPARg technology; and

     WHEREAS Omeros wishes to acquire all rights to Dr. Ciccocioppo’ PPARg technology and
related patent applications and patents; and

     WHEREAS Dr. Ciccocioppo wishes to sell all rights to his PPARg technology to Omeros in
consideration for Omeros undertaking certain future milestone and royalty obligations;

     NOW THEREFORE, in consideration for the mutual covenants and obligations set forth herein as
well as other good and valuable consideration, the parties hereby agree as follows:

	1	 	Definitions
	 
	1.1	 	“Intellectual Property Rights” shall mean all inventions, ideas, discoveries, issued,
reissued or reexamined patents, pending and future patent applications, continuation,
continuation-in-part and divisional patent applications, utility models, inventor’s
certificates, trade secrets, know-how, copyrights and trademarks.
	 
	1.2	 	“Assigned Patents” shall mean US Provisional Patent Application No. 60/911,201 filed April
11, 2007, US Patent Application No. 12/101,943 filed April 11, 2008, International Patent
Application PCT/US08/60146 filed April 11, 2008, all national and regional counterparts of
such International Patent Application, all patent applications claiming priority from the
foregoing patent applications, a provisional US Patent Application to be filed based on a
disclosure provided to Omeros on November 11, 2008 by Dr. Ciccocioppo entitled “Pioglitazone
and Opiates” and corresponding US Utility, International PCT and national phase applications
claiming priority therefrom, all other patent applications and patents included as of the
Effective Date or during the term of this Agreement in the Assigned IP, all future patents,
utility models and inventor’s certificates issuing from all of the above patent applications,
and all divisionals, continuations, continuation-in-parts, reissues and reexaminations of all
such patent applications and patents.
	 
	1.3	 	“Assigned IP” shall mean Dr. Ciccocioppo’s entire right and title to and interest in all
Intellectual Property Rights owned or held by Dr. Ciccocioppo related to PPARg
agonists,
compositions containing PPARg agonist(s) alone or in combination with other

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-1-

 

	 	 	therapeutic agents, and therapeutic methods and uses for PPARg agonists and
compositions containing PPARg agonist(s) alone or in combination with other
therapeutic agents, whether such compositions are administered alone or in conjunction with
other therapeutic agents or modalities, as of the Effective Date or invented, developed,
advanced or improved by Dr. Ciccocioppo during the term of this Agreement, including,
without limitation, methods and compositions for the use of PPARg agonists,
singly or in combination and/or in conjunction with other therapeutic agents, for prevention
and treatment related to alcoholism and addictive disorders (e.g., addictions to alcohol,
nicotine, marijuana, opioid agonists, benzodiazepine, barbiturates, psychostimulants and
addictive or compulsive behaviors), and the use of PPARg agonists in
combination and/or in conjunction with the administration of narcotic analgesics (e.g., to
delay or prevent the development of tolerance and/or addiction to opioid agonists) or for
the treatment of other central nervous system conditions, diseases and disorders, and all
improvements or inventions related to the foregoing examples, the Assigned Patents and all
inventions disclosed and/or claimed in the Assigned Patents, and the future right to file
US, ex-US and international patent applications for any other inventions that are included
in the Assigned IP or that become included in the Assigned IP during the term of this
Agreement, in Dr. Ciccocioppo’s name or in the name of Omeros, as well as all patents
issuing from such patent applications.
	 
	1.4	 	“Subject Products” shall mean all therapeutic compositions including one or more
PPARg agonists, alone or in combination with other therapeutic agents, that, if
offered for sale, sold, manufactured or used by a third party without license from Omeros
would infringe any valid, subsisting and enforceable claim(s) of any issued patent or any
patentable claim(s) of any pending patent application included within the Assigned Patents in
the country or countries in which such compositions are offered for sale, sold, manufactured
or used.
	 
	1.5	 	“Net Sales” shall refer, with respect to Subject Products, to (a) the gross total of the
monetary compensation invoiced and collected by Omeros for the initial sale or distribution of
the Subject Products, but excluding any amounts invoiced or collected by parties other than
Omeros for subsequent sales or distribution provided no part of such amounts invoiced or
collected by such parties is directly or indirectly paid to Omeros, less (b) the sum of the
following actual and customary deductions where applicable: cash, trade, or quantity
discounts; sales, use, tariff, import/export duties or other excise taxes, and any other
governmental taxes imposed on particular sales; transportation charges and allowances; sales
commissions to third parties (but excluding sales commissions to Omeros’ employees); wholesale
charge backs; distributor fees; Medicare/Medicaid rebates; customer rebates; refunds for
recalls; and allowances or credits to customers because of rejections or returns, provided
such deductions are documented. For purposes of this paragraph, the acquisition of Subject
Products from Omeros as part of an acquisition or other transfer or conveyance of all or a
part of the assets of Omeros’ business to which this Agreement pertains, or as part of a
merger, acquisition, reorganization or other change of control of Omeros, shall not be
considered a sale or
distribution of Omeros Therapeutics.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-2-

 

	 	 	If a Subject Product is sold in combination with one or more additional therapeutic agents
as a “Combination Product”, Net Sales shall be the product obtained by multiplying Net Sales
of the Combination Product by the fraction A/(A+B) where A is the sales price of such
Subject Product when sold separately as a composition in which the Subject Product is the
only therapeutic agent and B is the total sales price of all additional therapeutic agents
in the Combination Product when sold separately in a pharmaceutical therapeutic product
including such additional therapeutic agents as the only therapeutic agents. If such
Subject Product and the other therapeutic agents are not sold in separate pharmaceutical
therapeutic products, the portion of the total cost of the Combination Product attributed to
such Subject Product shall be a fraction, the numerator of which shall be the cost of the
Subject Product and the denominator of which shall be the total cost of the Combination
Product, and the fraction shall be multiplied by the sales price of the Combination Product
to arrive at Net Sales.
	 
	1.6	 	“Transfer Fees” shall mean any monetary compensation received by Omeros in connection with
the licensing, assignment or other conveyance of rights in the Assigned IP to third parties
for the manufacture, sale or distribution of Subject Products; provided, however, that the
Transfer Fees shall not include Net Sales or any compensation from such third parties to
Omeros to support Omeros’ research and development efforts, to resolve patent infringement
disputes concerning the Assigned IP or other Intellectual Property Rights, to purchase equity
in Omeros, for licensing under any other Intellectual Property Rights not included in Assigned
IP, or for any other purpose other than as direct compensation for the rights conveyed to such
third parties in the Assigned IP.
	 
	2	 	Assignment of Rights
	 
	2.1	 	In consideration of the obligations undertaken by Omeros in this Agreement,
Dr. Ciccocioppo hereby sells, assigns and transfers to Omeros
Dr. Ciccocioppo’s entire right and title to and interest in the
Assigned IP, including, without limitation, the Assigned Patents
and all other inventions, patent applications, patents and other
Intellectual Property Rights included therein, to be held and
enjoyed by Omeros entirely as the same would have been held and
enjoyed by Dr. Ciccocioppo had this sale, assignment and
transfer not been made. Dr. Ciccocioppo further agrees to
execute any memorandum of assignment or other assignment
documents as may be necessary or requested by Omeros to document
and perfect Omeros’ title in the Assigned IP including, without
limitation, the Assigned Patents and all other inventions,
patent applications, patents and other Intellectual Property
Rights included therein.
	 
	3	 	Royalty and Transfer Fee Share Payments
	 
	3.1	 	During the term of this Agreement Omeros shall pay Dr. Ciccocioppo on a [†] basis a
royalty of [†] of the Net Sales of Subject Products collected by Omeros during each
respective [†] (the “Royalty”); provided, however, that all Royalty payments owed by
Omeros to Dr. Ciccocioppo under this Section 3.1 shall be shared between and payable to
Dr. Ciccocioppo and Università di Camerino in accordance with Section 5 below, without
increase to the total Royalty owed by Omeros.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-3-

 

	3.2	 	During the term of this Agreement Omeros shall pay Dr. Ciccocioppo on a [†] basis a
share (the “Transfer Fee Share”) of any Transfer Fees collected by Omeros during each
respective quarter; provided, however, that all Transfer Fee Share payments owed by Omeros to
Dr. Ciccocioppo under this Section 3.2 shall be shared between and payable to Dr. Ciccocioppo
and Università di Camerino in accordance with Section 5 below, without increase to the total
Transfer Fee Share owed by Omeros. The Transfer Fee Share shall be (a) [†] of any
Transfer Fees collected by Omeros pursuant to an agreement between Omeros and a third party
that is executed prior to [†] for a Subject Product or (b) [†] of any
Transfer Fees collected by Omeros pursuant to an agreement between Omeros and a third party
that is executed on or after [†] for a Subject Product.
	 
	3.3	 	[†] Royalty and Transfer Fee Share payments shall be made in US Dollars by Omeros to
Dr. Ciccocioppo within [†] following the end of each [†] for Net Sales
realized during such [†]. Payments shall be computed based on a conversion from any
other denomination to US Dollars for any amounts collected by Omeros during the relevant
[†] using the prevailing exchange rate in effect at the date and time that funds are
transferred from Omeros’ account to Dr. Ciccocioppo’s account (in the case of payment by wire
transfer) or at the date and time of issuance of a check by Omeros (in the case of payment by
check). Each [†] payment shall be accompanied by a report specifying the source of
the Royalty payments and/or the Transfer Fee Share payments.
	 
	3.4	 	Dr. Ciccocioppo shall have the right to employ a certified public accountant to review and
reconcile the directly relevant accounting records and procedures of Omeros as they relate to
the determination of Royalty and/or Transfer Fee Share payments, during reasonable business
hours and no more than [†] a year, and Omeros agrees to make available at Omeros’
place of business all such directly relevant accounting records for that purpose within
[†] of written request by Dr. Ciccocioppo. The cost of such review shall be borne by
Dr. Ciccocioppo, unless it is found that Omeros under-paid a [†] Royalty or Transfer
Fee Share for any [†] by an amount of [†] or greater, in which case the cost
of such review shall be borne by Omeros.
	 
	3.5	 	Payments under this Agreement shall be made in full in the agreed amounts less any tax
withholdings that Omeros is required by law to withhold; provided that any other taxes that
may be due and payable as a result of Omeros’ payments to Dr. Ciccocioppo under this Agreement
are solely Dr. Ciccocioppo’s responsibility.
	 
	4	 	Milestone Payments
	 
	4.1	 	Omeros shall pay Dr. Ciccocioppo the following one-time development milestone payments (each
a “Milestone Payment”) upon completion by Omeros of the associated development activity (each
a “Development Milestone”); provided, however, that all Milestone Payments owed by Omeros to
Dr. Ciccocioppo under this Section 4.1 shall be shared between and payable to Dr. Ciccocioppo
and Università di Camerino in
accordance with Section 5 below, without increase to the total Milestone Payment owed by
Omeros. Omeros shall provide Dr. Ciccocioppo written notice of the completion of each
Development Milestone by Omeros within [†] of completion of such Development

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-4-

 

	 	 	Milestone and shall pay to Dr. Ciccocioppo the associated Milestone Payment within
[†] of completion of such Development Milestone. For purposes of clarity, upon
payment of a Milestone Payment in connection with the completion of the associated
Development Milestone for the development of a first Subject Product, no further Milestone
Payments for completion of the same associated Development Milestone for subsequent Subject
Products shall be payable.

	 	 	 
	Development Milestone	 	Milestone Payment
	[†]

	 	[†]
	[†]

	 	[†]
	[†]

	 	[†]
	[†]

	 	[†]
	[†]

	 	[†]

	5	 	University Payment Share
	 
	5.1	 	Omeros and Dr. Ciccocioppo acknowledge that Dr. Ciccocioppo invented certain of the
inventions included in the Assigned IP during the term of his employment with, and using the
facilities of, Università di Camerino. In accordance with an arrangement between Dr.
Ciccocioppo and Università di Camerino, [†] of each Royalty payment, Transfer Fee
payment and Milestone Payment payable in accordance with Sections 3 and 4 of this Agreement
shall be paid to Università di Camerino and the remaining [†] of each Royalty
payment, Transfer Fee payment and Milestone Payment payable in accordance with Sections 3and 4
of this Agreement shall be paid to Dr. Ciccocioppo.
	 
	5.2	 	Payments to be made to the Università di Camerino shall be provided to [†] by wire
transfer in accordance with the following instructions:
[†] ( Dr. Ciccocioppo shall provide Omeros prompt written notice of any changes to
the foregoing payment instructions during the term of this Agreement.
	 
	5.3	 	Payments to be made to Dr. Ciccocioppo shall be remitted by a wire transfer in accordance
with the following instructions:
	 
	 	 	[†]. Dr. Ciccocioppo shall provide
Omeros prompt written notice of any changes
to the foregoing payment instructions during
the term of this Agreement.
	 
	6	 	Right of Repurchase
	 
	6.1	 	If, at any point in time during the term of this Agreement in which Omeros retains ownership
of the Assigned IP or any part of the Assigned IP (the “Retained Assigned IP”), Omeros’
affirmatively determines, at Omeros’ sole discretion and as documented in
a written resolution by Omeros’ board of directors, to abandon all present and future
activities related to the Assigned IP and associated PPARg agonist programs,
including, without limitation, all patent, research, development, clinical studies,
partnering, licensing, transfer, regulatory, manufacturing, distribution and marketing
activities,

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-5-

 

	 	 	Omeros will promptly after the adoption of such resolution provide Dr.
Ciccocioppo a written notice of such determination (the “Notice of Abandonment”) including a
description of the Retained Assigned IP and the US dollar amount that equates to
[†] of the sum of all of Omeros’ financial investment in the Assigned IP and
Omeros’ related PPARg agonist research and/or development program(s) (the “Repurchase
Price”). For purposes of clarity, the Repurchase Price shall include [†] of all of
Omeros’ reasonably documented direct and indirect financial investments and expenditures,
including both out-of-pocket costs and the monetized costs of internal resource utilization.
Dr. Ciccocioppo shall have the first right to repurchase the Retained Assigned IP,
exercisable by (a) providing Omeros written notice of Dr. Ciccocioppo’s intention to
repurchase the Retained Assigned IP within [†] of Dr. Ciccocioppo’s receipt of the
Notice of Abandonment and (b) making payment in full to Omeros of the Repurchase Price
within [†] of Dr. Ciccocioppo’s receipt of the Notice of Abandonment.
	 
	6.2	 	Upon timely receipt of a notice of intention from Dr. Ciccocioppo and timely payment in full
of the Repurchase Price by Dr. Ciccocioppo, Omeros shall sell, transfer and convey to Dr.
Ciccocioppo all of Omeros’ rights and title to and interest in the Retained Assigned IP, and
thereafter Omeros shall be entitled to the receipt of, and Dr. Ciccocioppo shall be obligated
to pay Royalty payments, Transfer Fee Share payments and Milestone Payments from Dr.
Ciccocioppo, on the same terms as provided for Dr. Ciccocioppo in Sections 3.1, 3.2 and 4.1
above, in connection with Subject Products within the scope of the Retained Assigned IP.
	 
	6.3	 	If Dr. Ciccocioppo does not timely provide either a notice of intention to repurchase and/or
timely payment in full of the Repurchase Price, Omeros shall be free to sell, transfer, assign
or otherwise dispose of the Retained Assigned IP and the provisions of Sections 6.1 and 6.2
shall be of no further force or effect.
	 
	7	 	Patent Prosecution, Maintenance and Enforcement
	 
	7.1	 	Omeros as sole owner of the Assigned IP shall have the sole right, at its sole discretion and
expense, to file, prosecute, maintain and enforce the patents and patent applications within
the Assigned IP. Any litigation or other enforcement action undertaken by Omeros to enforce
the Assigned IP against infringing third parties shall be undertaken at Omeros’ sole
discretion and risk, and any resulting award, judgment, settlement or damages collected shall
belong solely to Omeros without duty to account to or share with Dr. Ciccocioppo. 

Dr.
Ciccocioppo shall reasonably assist Omeros in the filing, prosecution, maintenance and
enforcement of patents and patent applications within the Assigned IP for no additional
compensation but at no cost to Dr. Ciccocioppo.
Dr. Ciccocioppo shall execute all instruments and render all such assistance as Omeros may
reasonably request in order for Omeros to file, prosecute, maintain and enforce any and all
applications and patents within the Assigned IP, in the name of Omeros or in the
name of Dr. Ciccocioppo, all without charge to Omeros but at no expense to Dr. Ciccocioppo.
	 
	7.2	 	Dr. Ciccocioppo shall promptly provide written disclosure to Omeros of any inventions,

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-6-

 

	 	 	improvements, or applications included within the Assigned IP, made or arising before or
during the term of this Agreement. Dr. Ciccocioppo shall promptly provide written disclosure
to Omeros of any and all potentially material prior art known to
Dr. Ciccocioppo prior to the
Effective Date of this Agreement or
that becomes known to Dr.
Ciccocioppo during the term of this
Agreement.
	 
	8	 	Publication
	 
	8.1	 	Omeros and Dr. Ciccocioppo shall collaborate on any proposed scientific publications related
to the subject matter of the Assigned IP, including a discussion of scientifically appropriate
authorship and contents; provided, however, that Omeros acknowledges that only Dr. Ciccocioppo
and his collaborators shall be entitled to be named as authors in connection with the
publication of the results of research studies completed prior to the Effective Date of this
Agreement. Dr. Ciccocioppo shall furnish Omeros with advance copies of any publication or
written or oral public disclosure of the results of any research studies related to the
Assigned IP that is proposed by Dr. Ciccocioppo, including, without limitation, disclosures in
papers or abstracts or at research seminars, lectures, professional meetings, or poster
sessions, at least [†] prior to the proposed date for submission for publication or
disclosure. During such [†], Omeros shall have the right to review and comment on
such publication for accuracy and protection of Omeros’ Confidential Information.
Additionally, if Omeros so requests in writing during the foregoing [†], the proposed
submission for publication or disclosure shall be delayed beyond the proposed date for
publication or disclosure (the “Delay Period”) until Omeros has completed the filing of any
patent applications directed to information contained in such proposed publication or
disclosure or based on Omeros’ reasonable determination that publication should be delayed due
to other business considerations; provided, however, that the Delay Period shall not exceed
[†] without Dr. Ciccocioppo’s consent and that Omeros acknowledges that in any event
Dr. Ciccocioppo shall not be prohibited beyond [†] from submitting for publication
the results of research studies of the effect of PPAR-g agonists on alcoholism completed prior
to the Effective Date of this Agreement. Dr. Ciccocioppo agrees to consider in good faith any
delays longer that the Delay Period that may be reasonably requested by Omeros. Omeros shall
have the right, in its sole discretion, to use and disclose all data and results related to
the subject matter of the Assigned IP in connection with Omeros’ research, development,
commercialization and business activities, including, without limitation, in and for
submissions to any regulatory agencies and as may be required by law or regulation, and to
publish such data and results if Dr. Ciccocioppo does not wish to publish such data and
results.
	 
	9	 	Representations, Warranties and Other Obligations of Omeros
	 
	9.1	 	Omeros represents and warrants that it has the requisite corporate power and authority and
the legal right to enter into this Agreement and to perform its obligations hereunder.
	 
	9.2	 	Prior to Omeros’ marketing of any Subject Product, or making any Subject Product available
for use in any human patients, Omeros will obtain and maintain reasonably adequate product
liability insurance.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-7-

 

	10	 	Representations, Warranties and Other Obligations of Dr. Ciccocioppo
	 
	10.1	 	Dr. Ciccocioppo represents and warrants that he is the sole owner of, and has the lawful and
unrestricted right to assign, all right and title to and interest in the Assigned Patents and
to the Assigned IP, including, without limitation, all inventions and patent applications
included in the Assigned IP as of the Effective Date, and that except for payments owed to
Università di Camerino in accordance with Section 5 herein, the Assigned IP is not subject to
any encumbrances, liens, obligations, restrictions or licenses to third parties.
	 
	10.2	 	Except for any third party patents specific to PPARg compounds and compositions,
Dr. Ciccocioppo represents and warrants that he is not aware of any third party rights that
would be infringed as a result of Omeros’ development and commercialization of Subject
Products.
	 
	10.3	 	Dr. Ciccocioppo represents and warrants that he has provided to Omeros all material and
relevant data and results, in complete and accurate form including any contradictory data and
results, obtained from studies PPARg agonists conducted by Dr. Ciccocioppo and his
collaborators prior to the Effective Date of this Agreement.
	 
	10.4	 	Dr. Ciccocioppo covenants and agrees that, during the term of this Agreement, he shall not
undertake any obligations with third parties that would be inconsistent in any way with Dr.
Ciccocioppo’s transfer of the Assigned IP to Omeros or Dr. Ciccocioppo’s obligations under
this Agreement.
	 
	10.5	 	THE WARRANTIES SET FORTH EXPRESSLY IN THIS AGREEMENT ARE THE SOLE
WARRANTIES MADE BY EITHER PARTY TO THE OTHER AND THERE ARE NO OTHER WARRANTIES,
REPRESENTATIONS OR GUARANTEES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, REGARDING THE
SUBJECT PRODUCTS OR OTHER PRODUCTS, INCLUDING WITHOUT LIMITATION ANY EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
	 
	11	 	Confidentiality
	 
	11.1	 	Dr. Ciccocioppo and Omeros hereby affirm and incorporate by reference the terms of the Mutual
Nondisclosure Agreement between the parties dated March 5, 2008 concerning the subject matter
of this Agreement, except that all Confidential Information (as that term is defined in the
Mutual Nondisclosure Agreement) disclosed by Dr. Ciccocioppo related to the rights assigned to
Omeros under this Agreement shall be treated as Omeros’ Confidential Information under the
Mutual Nondisclosure Agreement, and Omeros shall be free to disclose and use such Confidential
Information, and to the extent that the terms
of the Mutual Nondisclosure Agreement may conflict with the terms of this Agreement, the terms of
this Agreement shall prevail. The parties further agree that the obligations of nondisclosure and
non-use set forth in such Mutual Nondisclosure Agreement shall subsist for a period of [†]
after the termination of this Agreement.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-8-

 

	11.2	 	The terms of this Agreement shall be maintained in strict confidence by both
Dr. Ciccocioppo and Omeros, and may not be
disclosed by either party without the consent of
the other party, except Omeros may disclose the
terms of this Agreement to Omeros’ current and
potential employees, officers, directors,
consultants, shareholders, investors and
corporate partners and either party may disclose
the terms of this Agreement as may be required
under a court order or decree or as required to
comply with any governmental law, rule or
regulation.
	 
	12	 	Limitation of Liability
	 
	12.1	 	Neither party shall be liable to the other party for any incidental, indirect, consequential
or special damages arising under this Agreement, under any theory including torts, even if
such damages may have been foreseeable.
	 
	13	 	Term and Termination
	 
	13.1	 	Unless terminated earlier as set forth in Section 13.2 below, this Agreement shall subsist so
long as there is any valid, subsisting and enforceable claim of any issued patent included
within the Assigned IP or any patentable claim in any pending patent application included
within the Assigned IP.
	 
	13.2	 	Either party may terminate this Agreement at any time in the event that the other party
breaches any material obligation of this Agreement after the party seeking to terminate this Agreement first submits a written
notice of breach to the breaching party, which breach is not
substantially cured within ninety (90) days of the receipt of such notice,
followed by written notice of termination then being sent to the breaching party.
	 
	13.3	 	Termination of this Agreement shall not act to nullify or affect Dr. Ciccocioppo’s assignment
of the Assigned IP to Omeros or the obligation of Omeros to pay to Dr. Ciccocioppo any Royalty
payments, Transfer Fee Share payments and Milestone Payments that have accrued prior to the
time of termination.
	 
	13.4	 	The provisions of Sections 1 (Definitions) 2 (Assignment of Rights), 7 (Patent Prosecution,
Maintenance and Enforcement), 8 (Publication), 9 (Representations, Warranties and Other
Obligations of Omeros), 10 (Representations, Warranties and Other Obligations of Dr.
Ciccocioppo), 11 (Confidentiality), 12 (Limitation of Liability), 14 (Use of Names) and 15
(Miscellaneous) of this Agreement shall survive expiration or termination of this Agreement
for the period set forth therein or, if no period is set forth therein, then indefinitely.
Any payment obligations that accrued prior to the date of termination under Sections 3
(Royalty and Transfer Fee Share Payments), 4 (Milestone Payments) and 5 (University Payment
Share), but not any payment obligations that would
otherwise accrue after the date of termination, shall remain payable upon termination.
	 
	14	 	Use of Names
	 
	14.1	 	Nothing contained in this Agreement confers any right to either party to use in advertising,
publicity, or other promotional activities any name, trade name, trademark,

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-9-

 

	 	 	or other designation of the other party hereto, and neither party shall make such use without the prior
written consent of the other party; provided however Omeros may through written, oral or
electronic communication disclose the existence of this Agreement and the name of Dr.
Ciccocioppo to Omeros’ current and potential employees, directors, consultants, shareholders,
investors and corporate partners, and as required to comply with any governmental law, rule or
regulation.
	 
	15	 	Miscellaneous
	 
	15.1	 	This Agreement including all appendices and exhibits attached hereto or incorporated by
reference herein constitutes the entire understanding of the parties hereto regarding the
subject matter of this Agreement, and no other representation, agreement, promise or
undertaking altering, modifying, taking from or adding to the terms of this Agreement shall
have any effect unless the same is reduced to writing and duly executed by the parties hereto.
In the event of any conflict between the main body of this Agreement and any attachments
thereto or documents incorporated by reference therein, the provisions of the main body of
this Agreement shall control.
	 
	15.2	 	Either party’s failure to enforce any provision of this Agreement will not be considered a
waiver of future enforcement of that or any other provision.
	 
	15.3	 	The laws of the state of Washington, United States, without regard to its conflict-of-laws
provisions, shall govern this Agreement, its interpretation and its enforcement, and any
disputes arising out of or related to this Agreement.
	 
	15.4	 	Any civil action prosecuted or instituted by either party as permitted herein above with
respect to any matters arising out of or related to this Agreement shall be brought in the
United States District Court located in Western District of Washington, United States (if
federal subject matter jurisdiction therein lies) or the King County Superior Court, State of
Washington, United States (if there is no subject matter jurisdiction in federal court), and
each party hereby consents to the exclusive jurisdiction and venue of such courts for such
purposes.
	 
	15.5	 	In the event that it is necessary for either party of this Agreement to take legal action to
enforce any of the terms, conditions or rights contained herein, or to defend any such action,
then the prevailing party in such action shall be entitled to recover from the other party all
reasonable attorneys fees, costs and expenses related to such legal action.
	 
	15.6	 	In the event that any portion of this Agreement is held invalid or unenforceable by a court
of law, that provision will be construed and reformed to permit enforcement of the provision
to the maximum extent permissible consistent with the parties’ original intent,
and if such construction is not possible, such provision shall be struck from this
Agreement, and the remainder of the Agreement shall remain in full force and effect as if
such provision had never been part of this Agreement.
	 
	15.7	 	For the purposes of this Agreement, the parties hereto are independent contractors, and
nothing in this Agreement shall be construed to place them in the relationship of partners,

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-10-

 

	 	 	principal and agent, employer/employee or joint venturers. Except as provided expressly
herein, each party agrees that it shall have no authority to bind or obligate the other party,
nor shall any party hold itself out as having such authority.
	 
	15.8	 	Neither party will be liable for failure or delay in performing any obligation under this
Agreement, or will be considered in breach of this Agreement, if such failure or delay is due
to a natural disaster or any cause reasonably beyond such party’s control, provided that such
party resumes performance as soon as possible following the end of the event that caused such
delay or failure of performance.
	 
	15.9	 	Dr. Ciccocioppo may not assign this Agreement or any obligation or right under this
Agreement, in whole or in part, without Omeros’ prior written consent, which consent will not
be unreasonably withheld. Dr. Ciccocioppo consents to Omeros’ assignment of this Agreement in
whole or in part in connection with the merger, consolidation or transfer of all or
substantially all of that portion of Omeros’ assets to which this Agreement relates. Subject
to these restrictions, this Agreement will be binding upon and will inure to the benefit of
the parties’ permitted successors and assignees.
	 
	15.10	 	Any notice required or permitted to be given hereunder by either party shall be in writing
and shall be (a) delivered personally, (b) sent by registered mail, return receipt requested,
postage prepaid, (c) sent by an internationally recognized courier service guaranteeing
next-day delivery, charges prepaid, or (d) delivered by facsimile (with the original promptly
sent by any of the foregoing manners) to the addresses or facsimile numbers of the other party
set forth below, or at such other addresses as may from time to time be furnished by similar
notice by either party. The effective date of any notice hereunder shall be the date of
receipt by the receiving party.

	 	 	 	 
	 	If to Omeros:

	 	If to Dr. Ciccocioppo:
	 	 
	 	 
	 	Attn: Chief Executive Officer

	 	Roberto Ciccocioppo, Ph.D.
	 	Omeros Corporation

	 	Vicolo San Silvestro n. 25
	 	1420 Fifth Avenue, Suite 2600

	 	Camerino, 62032
	 	Seattle, WA 98101

	 	Italy
	 	U.S.A.
	 	 
	 	 
	 	 
	 	And a copy to: General Counsel
	 	 
	 	     at the same address as above
	 	 
	 	 
	 	 
	 	Fax: (206) 676.5005

	 	E-mail: [†]
	 	Phone: (206) 676.5000
	 	 

	15.11	 	This Agreement may be executed in one or more counterparts, each of which will be considered
an original, and all of which will constitute the same instrument.

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-11-

 

     IN WITNESS WHEREOF, Omeros and Dr. Ciccocioppo have each acknowledged and accepted this
Agreement by signing or causing it to have been signed by a duly authorized official.

	 	 	 	 	 	 	 	 	 
	OMEROS CORPORATION	 	ROBERTO CICCOCIOPPO, PH.D.	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Gregory A. Demopulos
 

	 	Signed: 
	 	/s/ Roberto Ciccocioppo
 

	 	 
	 
	 	 	 	 	 	 	 	 
	Name:

	 	Gregory A. Demopulos, M.D.
	 	Date:
	 	February 24, 2009	 	 
	 
	 	 	 	 	 	 	 	 
	Title:

	 	Chairman & CEO
	 	Fax:
	 	0737 403325	 	 
	 
	 	 	 	 	 	 	 	 
	Date:

	 	February 20, 2009	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Fax:

	 	206.676.5005	 	 	 	 	 	 

     The Università di Camerino, employer of Roberto Ciccocioppo, through the undersigned official
thereof, confirms the accuracy of the representations in Section 10 above in as much as such
representations concern Università di Camerino, and hereby consents to all of the transactions
provided for in the above Agreement.

	 	 	 	 	 
	UNIVERSITà DI CAMERINO	 	 
	 
	 	 	 	 
	By:

	 	/s/ Mario Cocchioni
 

	 	 
	 
	 	 	 	 
	Name:

	 	Prof. Mario Cocchioni	 	 
	 
	 	 	 	 
	Title:

	 	Head of Department Medicina	 	 
	Sperimentale e Sanità Pubblica	 	 
	 
	 	 	 	 
	Date:

	 	February 25, 2009	 	 
	 
	 	 	 	 
	Fax:

	 	0737 403325	 	 

 

			
	†	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-12-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]